<SEC-DOCUMENT>0001140361-25-020353.txt : 20250523
<SEC-HEADER>0001140361-25-020353.hdr.sgml : 20250523
<ACCEPTANCE-DATETIME>20250523164636
ACCESSION NUMBER:		0001140361-25-020353
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250522
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250523
DATE AS OF CHANGE:		20250523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				562020050
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		25983092

	BUSINESS ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(619) 949-3681

	MAIL ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20049643_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:gyre="http://ir.catalystbiosciences.com/20250522" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_359ed5aa6f874131abcc4d1c735cfe4f" contextRef="c20250522to20250522" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_8d102cfac2804bb1af8424746fbd3d3f" contextRef="c20250522to20250522">0001124105</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_803372887618415e9ccf7b8533d26b1b" contextRef="c20250522to20250522">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="gyre-20250522.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250522to20250522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-22</xbrli:startDate><xbrli:endDate>2025-05-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_dd6d5cf9e32642a38dbf8c16e598d8bc" contextRef="c20250522to20250522">8-K</ix:nonNumeric></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <div>
        <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

        <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported): <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_91d6e86721774baab49dc237ba25a245" contextRef="c20250522to20250522" format="ixt:date-monthname-day-year-en">May 22, 2025</ix:nonNumeric></span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_7d8d572fcadb403f829276e949e4b529" contextRef="c20250522to20250522">Gyre Therapeutics, Inc.</ix:nonNumeric><br/>
        </div>

        <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_bb33256183f446c882f5d1684a551878" contextRef="c20250522to20250522" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
                </div>
              </div>
            </td>

    <td style="width: 34%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_8d92bb4352284594bf8f114142f7cd82" contextRef="c20250522to20250522">000-51173</ix:nonNumeric><br/>
                </div>
              </div>
            </td>

    <td style="width: 33%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_604b812ba52e4d6aa852e41a4047d38c" contextRef="c20250522to20250522">56-2020050</ix:nonNumeric><br/>
                </div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(State or other jurisdiction of incorporation)</div>
              </div>
            </td>

    <td style="width: 34%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Commission File Number)</div>
              </div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(IRS Employer Identification No.)</div>
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom;">
              <div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_96c889a6cedd469aa0e4388bfc85c6b3" contextRef="c20250522to20250522">12770 High Bluff Drive</ix:nonNumeric><br/>
                </div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_38cfc3bdc0f746a683101739e3306dd5" contextRef="c20250522to20250522">Suite 150</ix:nonNumeric><br/>
                </div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_723f14caecbb499fae776ec99a9fde6a" contextRef="c20250522to20250522">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_ee3abc12dea04833ad6016a8592ed7e5" contextRef="c20250522to20250522">CA</ix:nonNumeric></div>
              </div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_f8a4873ff60d4696a05c54271ecc9758" contextRef="c20250522to20250522">92130</ix:nonNumeric><br/>
                </div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Address of principal executive offices)</div>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: center; color: rgb(0, 0, 0);">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_4705e864a627483e937b0a093d7f02a6" contextRef="c20250522to20250522">858</ix:nonNumeric>)
            <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_1decce6865864e78941566c22eb0a586" contextRef="c20250522to20250522">567-7770</ix:nonNumeric></span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">N/A</div>

        <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
          following provisions (<span style="font-style: italic;">see</span>&#160;General Instruction A.2. below):</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 23.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_d707c5485fd54de3b817a493b39c119b" contextRef="c20250522to20250522" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 23.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_33cabbdd46b242f3b0eae829fb1afa0a" contextRef="c20250522to20250522" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 23.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_1f84ec9409714b849ecd5b6a2426f3e5" contextRef="c20250522to20250522" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 23.4pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_b8c6869e52b740718b2129a6a90155a0" contextRef="c20250522to20250522" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
              </td>

  </tr>


</table>
      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 24.62%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Trading Symbol(s)</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 38.38%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which</div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">registered</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_f63e077c2a484cdfb63d6ed4219b486f" contextRef="c20250522to20250522">Common Stock</ix:nonNumeric><br/>
                </div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 24.62%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_3a2598ab4fe7485585be5ae98a5fbc34" contextRef="c20250522to20250522">GYRE</ix:nonNumeric><br/>
                </div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 38.38%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="-sec-ix-hidden:Fact_803372887618415e9ccf7b8533d26b1b">The Nasdaq Capital Market</span><br/>
                </div>
              </div>
            </td>

  </tr>


</table>
      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
          chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0);">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_fd1d647883b84fb896f40088c7b767e6" contextRef="c20250522to20250522" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
          or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div>
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        </div>

        <!--PROfilePageNumberReset%Num%2%%%--> </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 55.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Entry into a Material Definitive Agreement.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On May 22, 2025, Gyre Therapeutics, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC, as
        representative of the several underwriters (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell 2,222,222 shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;), par value $0.001 per share, at a public offering price of $9.00
        per Share (the &#8220;Offering&#8221;). In addition, the Company has granted the Underwriters an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and
        commissions.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company estimates that net proceeds from the Offering will be approximately $18.5 million, after deducting the Underwriters&#8217; discounts and commissions
        and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering to advance its Phase 2 clinical trial of F351 in metabolic dysfunction-associated steatohepatitis-associated liver fibrosis in the
        United States, for research and development, manufacturing and scale-up, as well as for working capital and general corporate purposes.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Offering was made pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration No. 333-283237), which was filed on November 14,
        2024 and was declared effective on November 22, 2024, as supplemented by a prospectus supplement, dated May 22, 2025, filed with the Securities and Exchange Commission on May 23, 2025.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Offering is expected to close on May 27, 2025, subject to customary closing conditions. Pursuant to the Underwriting Agreement, the Company has agreed
        to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the Underwriters may be required to make because of such liabilities.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the
        Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">A copy of the opinion of Gibson, Dunn &amp; Crutcher LLP relating to the validity of the Shares is filed herewith as Exhibit 5.1.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 55.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(d)<span style="font-style: italic;"> Exhibits</span>.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">EXHIBIT INDEX</span></div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 5.42%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">No.</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0);"><a href="ef20049643_ex1-1.htm">1.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">Underwriting Agreement, dated as of May 22, 2025, between Gyre Therapeutics, Inc. and Jefferies LLC, as representative of the underwriters named therein.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0);"><a href="ef20049643_ex5-1.htm">5.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">Opinion of Gibson, Dunn &amp; Crutcher LLP</div>
            </td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0);"><a href="ef20049643_ex5-1.htm">23.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">Consent of Gibson, Dunn &amp; Crutcher LLP (contained in Exhibit 5.1)</div>
            </td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5.42%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0);">104</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 94%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0);">Cover page interactive data file (embedded within the inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SIGNATURE</div>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
          its behalf by the undersigned hereunto duly authorized.</div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 50.16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">GYRE THERAPEUTICS, INC.</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 50.16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50.16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0);">Date:<span style="font-weight: bold;"> May 23, 2025</span></div>
              </div>
            </td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0);">By:</div>
              </div>
            </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0);">/s/ Han Ying, Ph.D.</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 50.16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0);">Name:</div>
              </div>
            </td>

    <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0);">Han Ying, Ph.D.</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 50.16%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0);">Title:</div>
              </div>
            </td>

    <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: left; color: rgb(0, 0, 0);">Chief Executive Officer</div>
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br/>
        </div>

        <div><br/>
        </div>

        <div style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">3</span> </div>

        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

    </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ef20049643_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="font-weight: bold; text-align: right;"> Exhibit 1.1<br>
  </div>
  <div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2,222,222 Shares of Common Stock</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Gyre Therapeutics, Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>UNDERWRITING AGREEMENT</u></div>
    <div>&#160;</div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">May 22, 2025</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">JEFFERIES LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">As Representative of the several Underwriters</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">c/o JEFFERIES LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">520 Madison Avenue</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">New York, New York 10022</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Introductory.</font>&#160; Gyre Therapeutics, Inc., a Delaware corporation
      (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company</font>&#8221;), proposes to issue and sell to the several underwriters named in <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule A</u></font>
      (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Underwriters</font>&#8221;) an aggregate of 2,222,222 shares (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Firm Shares</font>&#8221;)


      of its common stock, par value $0.001 per share (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Common Stock</font>&#8221;).&#160; In addition, the Company has granted to the Underwriters an option to purchase up to an
      additional 333,333 shares of Common Stock as provided in Section 2.&#160; The additional 333,333 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Optional Shares</font>.&#8221;&#160; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Shares</font>.&#8221;&#160; Jefferies LLC (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Jefferies</font>&#8221;) <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">has agreed to act as
        representative of the several Underwriters (in such capacity, the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Representative</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">&#8221;) in connection with the offering and sale of the Shares.&#160; To the extent there are no additional underwriters listed on <u>Schedule A</u>, the term &#8220;Representatives&#8221; as used herein shall mean you, as Underwriter, and the
        term &#8220;Underwriters&#8221; shall mean either the singular or the plural, as the context requires.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company has prepared and filed with the Securities and Exchange Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Commission</font>&#8221;) a shelf registration statement on Form S-3, File No. 333&#8209;283237, including a base prospectus (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Base Prospectus</font>&#8221;)


      to be used in connection with the public offering and sale of the Shares.&#160; Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act
      of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Securities Act</font>&#8221;), including all documents incorporated or deemed to
      be incorporated by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A or 430B under the Securities Act, is called the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Registration Statement</font>.&#8221;&#160; Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Shares is called the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Rule 462(b) Registration Statement</font>,&#8221; and, from and after the date and time of filing of any such Rule 462(b) Registration Statement, the term &#8220;Registration Statement&#8221; shall include the Rule
      462(b) Registration Statement.&#160; The preliminary prospectus supplement dated May 22, 2025 describing the Shares and the offering thereof (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Preliminary Prospectus
        Supplement</font>&#8221;), together with the Base Prospectus, is called the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Preliminary Prospectus</font>,&#8221; and the Preliminary Prospectus and any other prospectus
      supplement to the Base Prospectus in preliminary form that describes the Shares and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">preliminary prospectus</font>.&#8221;&#160; As used herein, the term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Prospectus</font>&#8221; shall mean the final
      prospectus supplement to the Base Prospectus that describes the Shares and the offering thereof (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Final Prospectus Supplement</font>&#8221;), together with the Base
      Prospectus, in the form first used by the Underwriters to confirm sales of the Shares<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>or in the form first made available to the Underwriters by the Company to
      meet requests of purchasers pursuant to Rule 173 under the Securities Act.&#160; References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus
      components of such prospectus.&#160; As used herein, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Applicable Time</font>&#8221; is 6:50 p.m. (New York City time) on May 22, 2025.&#160; As used herein, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">free writing prospectus</font>&#8221; has the meaning set forth in Rule 405 under the Securities Act, and &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">General Disclosure Package</font>&#8221; means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule B</u></font> hereto and the information included in <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule B-1</u></font> hereto.&#160; As used herein, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#8220;Road Show&#8221;</font> means a &#8220;road show&#8221; (as defined in Rule 433 under the Securities Act) relating to the offering of the Shares contemplated hereby that is a &#8220;written
      communication&#8221; (as defined in Rule 405 under the Securities Act).&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Marketing Materials</font>&#8221; means any materials or information provided to investors by, or with the
      approval of, the Company in connection with the marketing of the offering of the Shares, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically).&#160; Promptly after execution and delivery
      of this Agreement, the Company will prepare and file the Prospectus in accordance with Rule 424(b)(5) under the Securities Act.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base
      Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein.&#160; All references in this Agreement to financial statements and schedules and other information which are &#8220;contained,&#8221; &#8220;included&#8221;
      or &#8220;stated&#8221; in, or &#8220;part of&#8221; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the General Disclosure Package or the Prospectus, and all other references
      of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule 462(b) Registration Statement, the
      Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the General Disclosure Package or the Prospectus, as the case may be.&#160; All references in this Agreement to amendments or supplements to the Registration Statement, the
      Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the General Disclosure Package or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended, and the
      rules and regulations promulgated thereunder (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exchange Act</font>&#8221;) that is or is deemed to be incorporated by reference in the Registration
      Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be.&#160; All references in this Agreement to (i) the Registration Statement, the Preliminary Prospectus, any preliminary
      prospectus, the Base Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and
      Retrieval System (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">EDGAR</font>&#8221;) and (ii) the Prospectus shall be deemed to include any &#8220;electronic Prospectus&#8221; provided for use in connection with the offering of the
      Shares as contemplated by Section 3(n) of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company hereby confirms its agreements with the Underwriters as follows:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Representations and Warranties of the Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date
      (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows:</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compliance with Registration Requirements.&#160; </font>The Registration Statement, including any Rule 462(b) Registration Statement, has been or will be declared effective by the
      Commission under the Securities Act.&#160; The Company has complied or will comply to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental information.&#160; No stop order suspending the effectiveness of the
      Registration Statement, including any Rule 462(b) Registration Statement, is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Each preliminary prospectus and the Prospectus when filed complied or will comply in all material respects with the Securities Act and,
      if filed with the Commission through EDGAR (except as may be permitted by Regulation S&#8209;T under the Securities Act), was identical to the copy thereof delivered to the Underwriters for use in connection with the issuance and sale of the Shares.&#160; Each
      of the Registration Statement, including any Rule 462(b) Registration Statement, and any post-effective amendment thereto, at the time it became or becomes effective and as of the date of this Agreement and as of the First Closing Date and as of each
      applicable Option Closing Date complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or
      necessary to make the statements therein not misleading.&#160; As of the Applicable Time, the General Disclosure Package did not, and at the First Closing Date and at each applicable Option Closing Date, the General Disclosure Package will not, contain
      any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160; The Prospectus, as amended or supplemented, as of its
      date, did not, and as of the First Closing Date and at each applicable Option Closing Date, will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
      the circumstances under which they were made, not misleading.&#160; The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, including any Rule
      462(b) Registration Statement, or any post-effective amendment thereto, the General Disclosure Package, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Underwriters
      furnished to the Company in writing by the Representative expressly for use therein, it being understood and agreed that the only such information furnished by the Representative to the Company consists of the information described in Section 9(b)
      below.&#160; There are no contracts or other documents required to be described in the Preliminary Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required.&#160; The Registration
      Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Ineligible Issuer Status.</font>&#160; The Company is not an &#8220;ineligible issuer&#8221; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the
      Securities Act.&#160; Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act.&#160; Each free
      writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects
      with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission or retention where required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the
      completion of the public offer and sale of the Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary
      prospectus unless such information has been superseded or modified as of such time.&#160; Except for the free writing prospectuses, if any, identified in <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule B</u></font>, and
      electronic road shows, if any, furnished to the Representative before first use, the Company has not prepared, used or referred to, and will not, without the Representative&#8217;s prior consent, prepare, use or refer to, any free writing prospectus.&#160; Each
      Road Show, when considered together with the General Disclosure Package, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of
      the circumstances under which they were made, not misleading.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font>&#160; &#160; &#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Distribution of Offering Material By the Company</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; Prior to the later of (i) the
      expiration or termination of the option granted to the several Underwriters in Section 2 and (ii) completion of the Underwriters&#8217; distribution of the Shares, the Company has not distributed and will not distribute any offering material in connection
      with the offering and sale of the Shares other than the Registration Statement, the General Disclosure Package, the Prospectus or any free writing prospectus reviewed and consented to by the Representative.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Incorporated Documents.</font>&#160; The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus and the
      Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable, and, when read together with the other information in the Preliminary Prospectus or the
      Prospectus, as applicable, do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
      misleading.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(e)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Exchange Act Compliance.</font>&#160; The documents incorporated or deemed to be incorporated by reference in the Preliminary Prospectus and the Prospectus, at the time they were or
      hereafter are filed with the Commission, and any free writing prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other
      information in the Preliminary Prospectus or the Prospectus, as applicable, at the time the Registration Statement and any amendments thereto became or become effective, as of the Applicable Time and as of the First Closing Date and as of each
      applicable Option Closing Date, as the case may be, will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to
      make the statements therein, in the light of the circumstances under which they were made, not misleading.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(f)</font>&#160;&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Statistical and Market-Related Data.</font>&#160; All statistical, demographic and market&#8209;related data included in the Registration Statement, the Preliminary Prospectus or the
      Prospectus are based on or derived from sources that the Company reasonably believes to be reliable and accurate.&#160; To the extent required, the Company has obtained the written consent for the use of such data from such sources.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting.</font>&#160; The Company has established and maintains disclosure
      controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#8217;s
      principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management
      of the Company for effectiveness as of the end of the Company&#8217;s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions for which they were established.&#160; Since the end of the Company&#8217;s most recent audited
      fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#8217;s internal control over financial reporting (whether or not remediated) and no change in the Company&#8217;s internal control over financial reporting that has
      materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.&#160; The Company is not aware of any change in its internal control over financial reporting that has occurred during its most
      recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">This Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; This Agreement has been duly authorized, executed and delivered
      by the Company.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Authorization of the Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Shares have been duly authorized for issuance
      and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Shares is not subject to any
      preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Applicable Registration or Other Similar Rights.&#160; </font>There are no persons with registration or other similar rights to have any equity or debt securities registered for
      sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Material Adverse Change</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; Except as otherwise disclosed in the Registration
      Statement, the General Disclosure Package and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the General Disclosure Package and the Prospectus: (i) there has been no material adverse
      change, or any development that would reasonably be expected to result in a material adverse change, in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or
      prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or
      perform its obligations hereunder (any such change being referred to herein as a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Material Adverse Change</font>&#8221;); (ii) the Company and its subsidiaries, considered as
      one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity,
      whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not
      entered into any transactions not in the ordinary course of business; and (iii) there has not been any material decrease in the capital stock of the Company or its subsidiaries or any material increase in any short-term or long-term indebtedness of
      the Company and its subsidiaries, considered as one entity, and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#8217;s
      subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Independent Accountants.</font>&#160; Grant Thornton Zhitong Certified Public Accountants LLP, which has expressed its opinion with respect to the financial statements (which term
      as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the General Disclosure Package and the Prospectus, is (i) an independent registered public accounting firm as required by
      the Securities Act, the Exchange Act and the rules of the Public Company Accounting Oversight Board (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PCAOB</font>&#8221;), (ii) in compliance with the applicable
      requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who
      has not requested such registration to be withdrawn.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(m)</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Financial Statements.</font>&#160; The financial statements filed with the Commission as a part of the Registration Statement, the General Disclosure Package and the Prospectus
      present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#8217; equity and cash flows for the periods
      specified.&#160; Such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">GAAP</font>&#8221;) applied on a
      consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto and except in the case of unaudited financial statements, which are subject to normal and recurring year-end adjustments and do not
      contain all footnotes as permitted by the applicable rules of the Commission.&#160; The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called
      for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.&#160; No other financial statements or supporting schedules are required to be included in the Registration Statement, the
      General Disclosure Package or the Prospectus.&#160; The financial data set forth in each of the Registration Statement, the General Disclosure Package and the Prospectus fairly present, in all material respects, the information set forth therein on a
      basis consistent with that of the audited financial statements contained in the Registration Statement, the General Disclosure Package and the Prospectus.&#160; To the Company&#8217;s knowledge, no person who has been suspended or barred from being associated
      with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting
      schedules or other financial data filed with the Commission as a part of the Registration Statement, the General Disclosure Package and the Prospectus.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(n)</font>&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company&#8217;s Accounting System.</font>&#160; The Company and each of its subsidiaries make and keep books and records that are accurate in all material respects and maintain a system
      of internal accounting controls sufficient to provide reasonable assurance that:&#160; (i) transactions are executed in accordance with management&#8217;s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of
      financial statements in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (iv) the recorded accountability for assets is
      compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
      Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(o)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Incorporation and Good Standing of the Company.</font>&#160; The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the
      jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to
      enter into and perform its obligations under this Agreement.&#160; The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of California and each other jurisdiction in which such qualification is
      required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to result in a
      Material Adverse Change.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(p)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Subsidiaries.</font>&#160; Each of the Company&#8217;s &#8220;subsidiaries&#8221; (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or
      organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing (or such equivalent concept to the extent it exists under the law of such jurisdiction) under the laws
      of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure
      Package and the Prospectus.&#160; Each of the Company&#8217;s subsidiaries is duly qualified as a non-U.S. corporation, partnership or limited liability company, as applicable, to transact business and is in good standing (or such equivalent concept to the
      extent it exists under the law of such jurisdiction) in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in
      good standing would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.&#160; All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#8217;s subsidiaries
      have been duly authorized and validly issued, are fully paid and nonassessable and are either wholly- or majority-owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or
      adverse claim.&#160; None of the outstanding capital stock or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary.&#160; The constitutive or organizational documents of each of the
      subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect.&#160; The Company does not own or control, directly or indirectly, any
      corporation, association or other entity other than the subsidiaries listed in Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10&#8209;K for the fiscal year ended December 31, 2024.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(q)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Capitalization and Other Capital Stock Matters.</font>&#160; The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the
      General Disclosure Package and the Prospectus under the caption &#8220;Capitalization&#8221; (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each case described in the
      Registration Statement, the General Disclosure Package and the Prospectus).&#160; The Common Stock (including the Shares) conforms in all material respects to the description thereof contained in the Registration Statement, the General Disclosure Package
      and the Prospectus.&#160; All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws.&#160; None of the
      outstanding shares of Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company.&#160; There are no authorized or outstanding options, warrants,
      preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the
      Registration Statement, the General Disclosure Package and the Prospectus.&#160; The descriptions of the Company&#8217;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the
      Registration Statement, the General Disclosure Package and the Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(r)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Stock Exchange Listing</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Common Stock is registered pursuant to Section
      12(b) or 12(g) of the Exchange Act and is listed on the Nasdaq Capital Market (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Nasdaq</font>&#8221;), and the Company has taken no action designed to, or likely to have the
      effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration
      or listing.&#160; To the Company&#8217;s knowledge, it is in compliance with all applicable listing requirements of Nasdaq.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(s)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required.&#160; </font>Neither the Company nor any of its subsidiaries is in violation of its
      charter or by&#8209;laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Default</font>&#8221;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement,
      mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective
      properties or assets are subject (each, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Existing Instrument</font>&#8221;), except for such Defaults as would not reasonably be expected, individually or in the
      aggregate, to result in a Material Adverse Change.&#160; The Company&#8217;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the General Disclosure Package and the
      Prospectus and the issuance and sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement, the General Disclosure Package and the Prospectus under the caption &#8220;Use of Proceeds&#8221;) (i) have
      been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by&#8209;laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company
      or any subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets
      of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable
      to the Company or any of its subsidiaries, except in the cases of clauses (ii) and (iii) as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.&#160; No consent, approval, authorization or other
      order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#8217;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby
      and by the Registration Statement, the General Disclosure Package and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable
      state securities or blue sky laws or FINRA (as defined below).&#160; As used herein, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Debt Repayment Triggering Event</font>&#8221; means any event or condition which gives, or
      with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion
      of such indebtedness by the Company or any of its subsidiaries.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(t)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Material Actions or Proceedings.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no action,
      suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would reasonably be
      expected, individually or in the aggregate, to result in a Material Adverse Change.&#160; No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or
      contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(u)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Intellectual Property Rights.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its
      subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration
      Statement, the General Disclosure Package and the Prospectus as being owned or licensed by them and which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Intellectual Property</font>&#8221;) and, to the Company&#8217;s knowledge, the conduct of their respective businesses does not and will not infringe, misappropriate or otherwise
      conflict in any material respect with any such rights of others.&#160; The Intellectual Property has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and, except as would not reasonably be
      expected, individually or in the aggregate, result in a Material Adverse Change, the Company is unaware of any facts which would form a reasonable basis for any such adjudication.&#160; To the Company&#8217;s knowledge: (i) there are no third parties who have
      rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the General Disclosure Package and the Prospectus as
      licensed to the Company or one or more of its subsidiaries; and (ii) there is no infringement by third parties of any Intellectual Property.&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and Prospectus
      and any related claims, assertions or challenges, there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company&#8217;s rights in or to any Intellectual Property, and the Company is
      unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability or scope of any Intellectual Property, and, except as would not reasonably be expected, individually
      or in the aggregate, result in a Material Adverse Change, the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or any of its subsidiaries infringes
      or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the General Disclosure Package and the Prospectus as under development, infringe or violate, any patent, trademark, trade
      name, service name, copyright, trade secret or other proprietary rights of others, and, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change, the Company is unaware of any facts which
      would form a reasonable basis for any such action, suit, proceeding or claim.&#160; The Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary,
      except for any non-compliance which would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change, and all such agreements are in full force and effect.&#160; To the Company&#8217;s knowledge, there are no material
      defects in any of the patents or patent applications included in the Intellectual Property.&#160; The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of
      appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company&#8217;s knowledge, no employee of the Company is in or has been in violation of any term of any
      employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such
      violation relates to such employee&#8217;s employment with the Company.&#160; The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in
      the Intellectual Property have been complied with and in all non-U.S. offices having similar requirements, all such requirements have been complied with.&#160; None of the Company owned Intellectual Property or technology (including information technology
      and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or any of their
      respective officers, directors or employees or otherwise in violation of the rights of any persons.&#160; The product candidates described in the Registration Statement, the General Disclosure Package and the Prospectus as under development by the Company
      or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">All Necessary Permits, etc.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and each
      subsidiary possess such valid and current certificates, authorizations or permits required by state, U.S. federal or non-U.S. regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the
      Registration Statement, the General Disclosure Package and the Prospectus (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Permits</font>&#8221;), except where the failure to so possess such Permits would not reasonably
      be expected, individually or in the aggregate, to result in a Material Adverse Change.&#160; Neither the Company nor any of its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to
      the revocation or modification of, or non&#8209;compliance with, any such certificate, authorization or permit, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(w)</font>&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Title to Properties.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries
      have good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section 1(m) above (or elsewhere in the Registration Statement, the General Disclosure Package or
      the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except where the failure to possess such title would not reasonably be expected, individually or in
      the aggregate, to result in a Material Adverse Change.&#160; The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as
      are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(x)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Rights of Immunity.</font>&#160; Except as provided by laws or statutes generally applicable to transactions of the type described in this Agreement, none of the Company&#8217;s PRC
      (as defined below) or Hong Kong subsidiaries or any of their respective properties, assets or revenues has any right of immunity under PRC law, Hong Kong law, New York law or United States law, from any legal action, suit or proceeding, from the
      giving of any relief in any such legal action, suit or proceeding, from set-off or counterclaim, from the jurisdiction of any PRC, Hong Kong, New York state or United States federal court, from service of process, attachment upon or prior judgment,
      or attachment in aid of execution of judgment, or from execution of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such court, with respect to its obligations, liabilities or
      any other matter under or arising out of or in connection with this Agreement.&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PRC</font>&#8221; means the People&#8217;s Republic of China, which for purposes hereof excludes
      Hong Kong, Macao and Taiwan.&#160; To the extent that the Company or any subsidiaries or any of their respective properties, assets or revenues may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings
      may at any time be commenced, the Company and each of the subsidiaries waives or will waive such right to the extent permitted by law and has consented to such relief and enforcement as provided in Section 19 of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(y)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Tax Law Compliance.</font>&#160; The Company and its subsidiaries have filed all necessary U.S. federal, state and non-U.S. income and franchise tax returns or have properly
      requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by
      appropriate proceedings and except where the failure to file or pay would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.&#160; The Company has made adequate charges, accruals and reserves in the
      applicable financial statements referred to in Section 1(m) above in respect of all U.S. federal, state and non-U.S. income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been
      finally determined.&#160; All material local and national PRC and Hong Kong governmental tax holidays, exemptions, waivers, financial subsidies, and other local and national PRC and Hong Kong tax relief, concessions and preferential treatment enjoyed by
      the Company, the PRC Entity (as defined below) or its Hong Kong subsidiary as described in the Registration Statement, the General Disclosure Package and the Prospectus are valid, binding and enforceable and do not violate any laws, regulations,
      rules, orders, decrees, guidelines, judicial interpretations, notices or other legislation of the PRC or Hong Kong.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(z)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company Not an &#8220;Investment Company.&#8221;</font>&#160; The Company is not, and will not be, either after receipt of payment for the Shares or after the application of the proceeds
      therefrom as described under &#8220;Use of Proceeds&#8221; in the Registration Statement, the General Disclosure Package and the Prospectus, required to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Investment Company Act</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(aa)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Insurance.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, each of the Company and its subsidiaries are
      insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to,
      policies covering material real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product
      liability claims and clinical trial liability claims.&#160; The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable
      coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to result in a Material Adverse Change.&#160; Neither the Company nor any of its
      subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(bb)</font>&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Price Stabilization or Manipulation; Compliance with Regulation M.</font>&#160; Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action
      designed to or that, without giving effect to activities by the Underwriters that were not consented to or directed by the Company, would reasonably be expected to cause or result in stabilization or manipulation of the price of the Common Stock or
      of any &#8220;reference security&#8221; (as defined in Rule 100 of Regulation M under the Exchange Act (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Regulation M</font>&#8221;)) with respect to the Common Stock, whether to
      facilitate the sale or resale of the Shares or otherwise, and has taken no action which, without giving effect to activities by the Underwriters that were not consented to or directed by the Company, would directly or indirectly violate Regulation M.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(cc)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Related Party Transactions.</font>&#160; There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person
      required to be described in the Registration Statement, the General Disclosure Package or the Prospectus which have not been described as required.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(dd)</font>&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">FINRA Matters.</font>&#160; All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors and, to
      the Company&#8217;s knowledge, the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete, correct and compliant in all material respects with Financial
      Industry Regulatory Authority, Inc.&#8217;s (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">FINRA</font>&#8221;) rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or
      NASD Conduct Rules is true, complete and correct in all material respects.&#160; The Company meets the definition of the term &#8220;experienced issuer&#8221; specified in FINRA Rule 5110(j)(6).</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(ee)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Unlawful Contributions or Other Payments.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, neither the
      Company nor any of its subsidiaries nor, to the Company&#8217;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any U.S. federal, state or non-U.S. office
      in violation of any law or of the character required to be disclosed in the Registration Statement, the General Disclosure Package and the Prospectus.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">11</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(ff)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compliance with Environmental Laws.</font>&#160; Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, and except as would not
      reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change; (i) neither the Company nor any of its subsidiaries is in violation of any U.S. federal, state, local or non-U.S. statute, law, rule, regulation,
      ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment
      (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants,
      contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Hazardous Materials</font>&#8221;) or to the manufacture,
      processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Environmental Laws</font>&#8221;), (ii) the Company
      and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (iii) there are no pending or, to the Company&#8217;s knowledge, threatened
      administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of non-compliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and
      (iv) there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the
      Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(gg)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Periodic Review of Costs of Environmental Compliance.</font>&#160; In the ordinary course of its business, the Company conducts a periodic review of the effect of Environmental Laws
      on the business, operations and properties of the Company and its subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required for
      clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties).&#160; No facts or circumstances have come to the
      Company&#8217;s attention that could result in costs or liabilities that could be expected, individually or in the aggregate, to result in a Material Adverse Change.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(hh)</font>&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">ERISA Compliance.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, and except as would not reasonably be
      expected, individually or in the aggregate, to result in a Material Adverse Change, the Company and its subsidiaries and any &#8220;employee benefit plan&#8221; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the
      regulations and published interpretations thereunder (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">ERISA</font>&#8221;)) established or maintained by the Company, its subsidiaries or their &#8220;ERISA
      Affiliates&#8221; (as defined below) are in compliance in all material respects with ERISA.&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">ERISA Affiliate</font>&#8221; means, with respect to the Company or any of its
      subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Code</font>&#8221;) of which the Company or such subsidiary is a member.&#160; Except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change, (i) no
      &#8220;reportable event&#8221; (as defined under ERISA), for which notice has not been waived, has occurred or is reasonably expected to occur with respect to any &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their
      ERISA Affiliates, (ii) no &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would have any &#8220;amount of unfunded benefit liabilities&#8221;
      (as defined under ERISA), and (iii) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any
      &#8220;employee benefit plan&#8221; or (ii) Sections 412, 4971, 4975 or 4980B of the Code.&#160; Each &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section
      401(a) of the Code has received a favorable determination or opinion letter from the Internal Revenue Service or has time remaining to do so, and to the knowledge of the Company, whether by action or failure to act, which would cause the loss of such
      qualification.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">12</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Brokers.</font>&#160; Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no broker, finder or other party that
      is entitled to receive from the Company any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(jj)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Outstanding Loans or Other Extensions of Credit.&#160; </font>The Company does not have any outstanding extension of credit, in the form of a personal loan, to or for any
      director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(kk)</font>&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compliance with Laws.</font>&#160; The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure to be so in
      compliance would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(ll)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Dividend Restrictions.</font>&#160; Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, no subsidiary of the Company is prohibited
      or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#8217;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts
      that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(mm)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Anti-Corruption and Anti-Bribery Laws.</font>&#160; Neither the Company nor any of its subsidiaries, nor to the knowledge of the Company, any director, officer, employee, agent,
      affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift,
      entertainment or other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any non-U.S. or domestic government
      official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the
      U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">FCPA</font>&#8221;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or
      (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit.&#160; The Company and its subsidiaries and, to the knowledge of the Company,
      the Company&#8217;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
      therewith.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(nn)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Money Laundering Laws.</font>&#160; The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial
      recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar
      applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Money Laundering Laws</font>&#8221;) and no
      action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the Company&#8217;s knowledge,
      threatened.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">13</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(oo)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Clinical Data and Regulatory Compliance.</font>&#160; The preclinical tests and clinical trials, and other studies (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">studies</font>&#8221;) that are described in, or the results of which are referred to in, the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in all
      material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete
      in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results
      described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug
      Administration of the U.S. Department of Health and Human Services or any committee thereof, the PRC National Medical Products Administration or any committee thereof or from any other U.S. or non-U.S. government or drug or medical device regulatory
      agency, or health care facility Institutional Review Board (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Regulatory Agencies</font>&#8221;); neither the Company nor any of its subsidiaries has
      received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the General Disclosure Package or the
      Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(pp)</font>&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Sanctions.</font>&#160; Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, after due inquiry, any director, officer, employee, agent, affiliate
      or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department
      of State, the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Sanctions</font>&#8221;);


      nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, the Crimea Region of Ukraine, the so-called Donetsk People&#8217;s
      Republic, the so-called Luhansk People&#8217;s Republic, the non-government controlled areas of Zaporizhzhia and Kherson regions of Ukraine, Cuba, Iran, North Korea, and Syria (each, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Sanctioned Country</font>&#8221;); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or
      other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result
      in a violation by any person (including any person participating in the transactions contemplated hereby whether as underwriter, advisor, investor or otherwise) of applicable Sanctions.&#160; For the past ten years, the Company and its subsidiaries have
      not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(qq)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Sarbanes-Oxley.</font>&#160; The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations
      promulgated thereunder.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">14</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(rr)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Duties, Transfer Taxes, Etc.</font>&#160; No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other taxes are payable by the
      Underwriters in the United States, Hong Kong or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the
      Shares.&#160; No transaction, stamp, capital or other issuance, registration, transaction, transfer or withholding taxes or duties are payable in the PRC by or on behalf of the Underwriters to any PRC taxing authority in connection with (i) the execution
      and delivery of this Agreement or (ii) the consummation of the transactions contemplated hereunder, given that all of the above activities mentioned in clauses (i) and (ii) above shall take place outside of the PRC.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(ss)</font>&#160;&#160;&#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Cybersecurity.</font>&#160; The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications,
      and databases (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IT Systems</font>&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the
      business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.&#160; The Company and its subsidiaries have implemented and maintained
      commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT
      Systems and data, including &#8220;Personal Data,&#8221; used in connection with their businesses.&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Personal Data</font>&#8221; means (i) a natural person&#8217;s name, street address,
      telephone number, e-mail address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify
      as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) &#8220;personal data&#8221; as defined by GDPR (as defined below); (iv) any information which would qualify as &#8220;protected health information&#8221; under the Health
      Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">HIPAA</font>&#8221;);


      and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation.&#160; To the Company&#8217;s
      knowledge, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under
      internal review or investigations relating to the same.&#160; The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
      governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
      misappropriation or modification.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(tt)</font>&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compliance with Data Privacy Laws.</font> The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data
      privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in
      compliance with, the European Union General Data Protection Regulation (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">GDPR</font>&#8221;) (EU 2016/679) (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Privacy Laws</font>&#8221;).&#160; To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all
      material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Policies</font>&#8221;).&#160; The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained
      in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect.&#160; The Company further certifies that neither it nor any subsidiary: (i) has
      received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice;
      (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability
      under any Privacy Law.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">15</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(uu)</font>&#160;&#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Parties to Lock-Up Agreements</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company has furnished to the Underwriters a
      letter agreement in the form attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit A</u></font> (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Lock-up Agreement</font>&#8221;)
      from each of the persons listed on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit B</u></font>.&#160; Such <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit B</u></font> lists under an appropriate
      caption the directors and officers of the Company.&#160; If any additional persons shall become directors or officers of the Company prior to the end of the Lock-up Period (as defined below), the Company shall cause each such person, prior to or
      contemporaneously with their appointment or election as a director or officer of the Company, to execute and deliver to the Representative a Lock-up Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(vv)</font>&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Forward-Looking Statements.</font>&#160; Each financial or operational projection or other &#8220;forward-looking statement&#8221; (as defined by Section 27A of the Securities Act or Section
      21E of the Exchange Act) contained in the Registration Statement, the General Disclosure Package or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying
      assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking
      statement.&#160; No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(ww)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compliance with Health Care Laws.&#160; </font>The Company and its subsidiaries are, and at all times have been, in compliance in all material respects with all applicable Health
      Care Laws.&#160; For purposes of this Agreement, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Health Care Laws</font>&#8221; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public
      Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable U.S. federal, state, local and non-U.S. health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42
      U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42
      U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h),
      and applicable laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and
      Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable U.S. federal, state, local or non-U.S. laws or regulatory bodies; (vi)
      all other local, state, U.S. federal, national, supranational and non-U.S. laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S.
      counterpart thereof.&#160; Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or
      regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
      or other action threatened.&#160; The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care
      Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent
      submission).&#160; Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory
      authority.&#160; Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human
      clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">16</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(xx)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Market Capitalization.</font>&#160; At the time the Registration Statement was originally filed, the Company met the then applicable requirements for the use of Form S-3 under the
      Securities Act, including General Instruction I.B.1 of Form S-3.&#160; As of the date of this Agreement, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405 under the Securities Act) of the Company
      held by persons other than affiliates of the Company (pursuant to Rule 144 under the Securities Act, those that, directly or indirectly through one or more intermediaries, control or are controlled by, or are under common control with, the Company)
      (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Non-Affiliate Shares</font>&#8221;), was equal to or greater than $75 million (calculated by multiplying (x) the highest price at which the common equity of the Company
      closed on Nasdaq within 60 days of the date the Registration Statement was declared effective times (y) the number of Non-Affiliate Shares).&#160; The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a
      shell company for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current Form 10 information (as defined in Instruction I.B.6 of Form S-3) with the Commission at least 12 calendar months
      previously reflecting its status as an entity that is not a shell company.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(yy)</font>&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Payments in Foreign Currency.</font>&#160; Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, under current laws and regulations
      of the United States, Hong Kong and any political subdivision thereof, all dividends and other distributions declared and payable on the Shares may be paid by the Company to the holder thereof in United States dollars that may be converted into
      foreign currency and may be freely transferred out of the United States and Hong Kong and all such payments made to holders thereof or therein who are non-residents of the United States or Hong Kong will not be subject to income, withholding or other
      taxes under laws and regulations of the United States or Hong Kong or any political subdivision or taxing authority thereof or therein and without the necessity of obtaining any governmental authorization in the United States and Hong Kong or any
      political subdivision or taxing authority thereof or therein.&#160; Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all dividends and other distributions declared and payable on the share capital of
      the subsidiaries of the Company that are organized in the PRC may, under the current laws and regulations of the PRC and after full payment of withholding tax, as applicable, be freely transferred out of the PRC and may be paid in United States
      dollars, provided that the remittance of such dividends and other distributions outside of the PRC complies with the procedures required under the PRC laws and by the relevant governmental agencies relating to foreign exchange, without other consent,
      approval, authorization or order of, or qualification with, any court or governmental agency or body in such entity&#8217;s jurisdiction of incorporation or tax residence, and all such dividends and other distributions will not be subject to other taxes
      under the laws and regulations of the PRC and are otherwise free and clear of any other tax, withholding or deduction in the PRC, and without the necessity of obtaining any governmental authorization in the PRC.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">17</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(zz)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">CSRC Filings.</font>&#160; The Company is aware of and has been advised as to, the content of the Trial Measures for the Administration of Overseas Securities Offering and Listing
      by Domestic Enterprises and any official clarifications, guidance, interpretations or implementation rules in connection with or related thereto (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CSRC Filing Rules</font>&#8221;)


      promulgated by the Chinese Securities Regulatory Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CSRC</font>&#8221;) on February 17, 2023, including the relevant provisions thereof which purport to require
      that the follow-on offering of shares of an issuer in the same overseas market where it has previously issued and listed securities shall be filed with and reported to the CSRC within the prescribed timeframe.&#160; Provided that the issuance and sale of
      all of the Shares is registered under the Registration Statement (excluding any Rule 462(b) Registration Statement), the listing and trading of such Shares on Nasdaq and the consummation of the transactions contemplated by this Agreement do not
      require prior filing with or approval of the CSRC, but a report to the CSRC of the overall offering information in a consolidated manner is required after completion of issuance and sale of all securities, including but not limited to the Shares, to
      be issued under the Registration Statement (excluding any Rule 462(b) Registration Statement). If the issuance and sale of any of the Shares is registered under an additional Rule 462(b) Registration Statement, the listing and trading of such Shares
      on Nasdaq and the consummation of the sale of such Shares contemplated by this Agreement will not require the prior filing with or approval of the CSRC, but will require filing with the CSRC within three business days after the completion of the
      issuance and offering of such Shares hereunder.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(aaa)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compliance with PRC Regulations on PRC Overseas Investment.</font>&#160; The Company has taken all reasonable steps to comply with, and has made reasonable efforts to ensure
      compliance by each of its shareholders, option holders, directors, officers and employees that is, or is directly or indirectly owned or controlled by, a PRC resident or citizen with any applicable rules and regulations of the relevant PRC government
      agencies (including but not limited to the Ministry of Commerce, the National Development and Reform Commission, the CSRC and the State Administration of Foreign Exchange) relating to overseas investment by PRC residents and citizens (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PRC Overseas Investment Regulations</font>&#8221;), including requesting each shareholder, option holder, director, officer and employee that is, or is directly or indirectly
      owned or controlled by, a PRC resident or citizen to complete any registration and other procedures required under applicable PRC Overseas Investment Regulations.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(bbb)</font>&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Final Judgments.</font>&#160; Any final judgment for a fixed or readily calculable sum of money rendered by a Specified Court (as defined below) having jurisdiction under its own
      domestic laws in respect of any suit, action or proceeding against the Company based upon this Agreement and any instruments or agreements entered into for the consummation of the transactions contemplated herein and therein would be recognized and
      enforced against the Company in the courts of the Hong Kong and the PRC (as the case may be), without re-examination or review of the merits of the cause of action in respect of which the original judgment was given or re-litigation of the matters
      adjudicated upon, by the courts of Hong Kong and the PRC, provided that with respect to courts of the PRC, subject to the uncertainties in respect of PRC courts&#8217; recognition and enforcement of foreign judgments disclosed in the Registration
      Statement, the General Disclosure Package and Prospectus, (A) adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard, (B) such judgments or the enforcement thereof are not contrary to the law,
      public policy, security or sovereignty of the PRC, (C) such judgments were not obtained by fraudulent means and do not conflict with any other valid judgment in the same matter between the same parties and (D) an action between the same parties in
      the same matter is not pending in any PRC court at the time the lawsuit is instituted in a foreign court.&#160; The Company is not aware of any reason why the enforcement in Hong Kong or the PRC of such a Specified Court judgment would be, as of the date
      hereof, contrary to public policy of Hong Kong or the PRC.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(ccc)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Indemnification and Contribution.</font>&#160; The indemnification and contribution provisions set forth in Sections 9 and 10 hereof do not contravene PRC law or public policy.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the
      Underwriters in connection with the offering, or the purchase and sale, of the Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">18</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company has a reasonable basis for making each of the representations set forth in this Section 1.&#160; The Company acknowledges that the
      Underwriters and, for purposes of the opinions to be delivered pursuant to<font style="font-size: 10pt; font-family: 'Times New Roman';"> Section 6</font> hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and
      truthfulness of the foregoing representations and hereby consents to such reliance.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Purchase, Sale and Delivery of the Shares</font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">The Firm Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; Upon the terms herein set forth, the Company agrees to issue
      and sell to the several Underwriters an aggregate of 2,222,222 Firm Shares.&#160; On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree,
      severally and not jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule A</u></font>.&#160; The purchase price per Firm
      Share to be paid by the several Underwriters to the Company shall be $8.46 per share.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">The First Closing Date</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; Delivery of the Firm Shares to be purchased by the
      Underwriters and payment therefor shall be made at the offices of Wilmer Cutler Pickering Hale and Dorr LLP (or such other place as may be agreed to by the Company and the Representative) at 9:00 a.m. New York City time, on May 27, 2025 or such other
      time and date not later than 1:30 p.m. New York City time, on June 10, 2025 as the Representative shall designate by notice to the Company (the time and date of such closing are called the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">First Closing Date</font>&#8221;).&#160; The Company hereby acknowledges that circumstances under which the Representative may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited
      to, any determination by the Company or the Representative to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section 11.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">(c)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; color: #000000;">The Optional Shares; Option Closing Date</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">&#160; In addition, on the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, </font>the
      Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 333,333 Optional Shares from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares,
      less an amount per share equal to any dividend or distribution declared by the Company and payable on the Firm Shares but not payable on Optional Shares.&#160; The option granted hereunder may be exercised at any time and from time to time in whole or in
      part upon notice by the Representative to the Company, which notice may be given at any time within 30 days from the date of this Agreement.&#160; Such notice shall set forth (i) the aggregate number of Optional Shares as to which the Underwriters are
      exercising the option and (ii) the time, date and place at which the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are
      simultaneous with the First Closing Date, the term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">First Closing Date</font>&#8221; shall refer to the time and date of delivery of the Firm Shares and such Optional
      Shares).&#160; Any such time and date of delivery, if subsequent to the First Closing Date, is called an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Option Closing Date</font>,&#8221; and shall be determined by the
      Representative and shall not be earlier than one or later than five full business days after delivery of such notice of exercise.&#160; If any Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number
      of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representative may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule A</u></font> opposite the name of such Underwriter bears to the total number of Firm Shares.&#160; The Representative may cancel the option at any time prior to its expiration <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">by giving written notice of such cancellation to the Company.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">19</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Public Offering of the Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Representative hereby advises the Company
      that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the General Disclosure Package and the Prospectus, their respective portions of the Shares as soon after this Agreement has
      been executed as the Representative, in its sole judgment, has determined is advisable and practicable.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Payment for the Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; (i) Payment for the Shares shall be made at the First
      Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">It is understood that
        the Representative has been authorized, for its own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters
        have agreed to purchase.&#160; Jefferies, individually and not as the Representative of the Underwriters, may (but shall not be obligated to) make payment for any Shares to be purchased by any Underwriter whose funds shall not have been received by the
        Representative by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Delivery of the Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company shall deliver, or cause to be delivered, to
      the Representative for the accounts of the several Underwriters the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor.&#160; The Company shall also
      deliver, or cause to be delivered to the Representative for the accounts of the several Underwriters, the Optional Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the case may be,
      against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor.&#160; If the Representative so elects, delivery of the Shares may be made by credit to the accounts designated by the Representative
      through The Depository Trust Company&#8217;s full fast transfer or DWAC programs.&#160; If the Representative so elects, any certificates for the Shares shall be registered in such names and denominations as the Representative shall have requested at least two
      full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the applicable Option Closing Date, as
      the case may be) at a location in New York City as the Representative may designate.&#160; Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Additional Covenants of the Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company further covenants and agrees with each Underwriter as follows:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Delivery of Registration Statement, General Disclosure Package and Prospectus.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>
      The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Shares is required by the
      Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Shares, as many copies of the General Disclosure Package, the Prospectus and any
      supplements and amendments thereto or to the Registration Statement as you may reasonably request.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">20</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Representative&#8217;s Review of Proposed Amendments and Supplements.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font> During the
      period when a prospectus relating to the Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i) will furnish to the
      Representative for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii) will not amend or supplement the
      Registration Statement (including any amendment or supplement through incorporation of any report filed under the Exchange Act) without the Representative&#8217;s prior written consent.&#160; Prior to amending or supplementing any preliminary prospectus, the
      General Disclosure Package or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representative for review, a reasonable amount of time prior to
      the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement.&#160; The Company shall not file or use any such proposed amendment or supplement without the Representative&#8217;s prior written consent.&#160;
      The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Free Writing Prospectuses.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font> The Company shall furnish to the Representative for
      review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and
      the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representative&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed.&#160; The Company
      shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request.&#160; If at any time when a prospectus is
      required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Shares (but in any event if at any time through and including the
      First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in
      the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such
      time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue
      statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representative for review, a reasonable amount of time prior
      to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the
      Representative&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Filing of Underwriter Free Writing Prospectuses.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font> The Company shall not take
      any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter
      otherwise would not have been required to file thereunder.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">21</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Amendments and Supplements to General Disclosure Package.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font> If the General
      Disclosure Package is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or
      supplement the General Disclosure Package so that the General Disclosure Package does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
      circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the General Disclosure Package conflicts with the information contained in the Registration Statement, or if,
      in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the General Disclosure Package to comply with applicable law, the Company shall (subject to Section 3(b) and Section 3(c) hereof) promptly prepare, file with the
      Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the General Disclosure Package so that the statements in the General Disclosure Package as so amended or supplemented
      will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the
      General Disclosure Package, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the General Disclosure Package, as amended or supplemented, will comply with applicable law.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Certain Notifications and Required Actions</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; After the date of this Agreement,
      the Company shall promptly advise the Representative in writing of:&#160; (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) the time and date of any filing of any post-effective amendment
      to the Registration Statement or any amendment or supplement to any preliminary prospectus, the General Disclosure Package, any free writing prospectus or the Prospectus; (iii) the time and date that any post-effective amendment to the Registration
      Statement becomes effective; and (iv) the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary prospectus,
      the General Disclosure Package or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the General Disclosure Package, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend
      or terminate from listing or quotation the Common Stock from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.&#160; If the
      Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order as soon as reasonably practicable.&#160; Additionally, the Company agrees that it shall comply with all applicable provisions
      of Rule 424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Amendments and Supplements to the Prospectus and Other Securities Act Matters.</font>&#160; If any event shall occur or condition exist as a result of which it is necessary to amend
      or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is
      delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the Representative or counsel for the Underwriters it is otherwise necessary to
      amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section 3(b) and Section 3(c)) hereof to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any
      dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to
      make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the
      Prospectus, as amended or supplemented, will comply with applicable law.&#160; Neither the Representative&#8217;s consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#8217;s obligations under Section 3(b) or
      Section 3(c).</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">22</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(h)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Blue Sky Compliance</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company shall cooperate with the Representative and
      counsel for the Underwriters to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions
      designated by the Representative, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares.&#160; The Company shall not be required to qualify as a
      foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.&#160; The Company will advise the
      Representative promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and
      in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as reasonably practicable.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Use of Proceeds</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company shall apply the net proceeds from the sale of the
      Shares sold by it in the manner described under the caption &#8220;Use of Proceeds&#8221; in the Registration Statement, the General Disclosure Package and the Prospectus.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Transfer Agent</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company shall engage and maintain, at its expense, a
      registrar and transfer agent for the Common Stock.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Earnings Statement</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company will make generally available to its security
      holders and to the Representative as soon as reasonably practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this
      Agreement that will satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>,
      that the requirements of this Section 3(k) shall be satisfied to the extent that such earnings statement is available on EDGAR.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(l)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Continued Compliance with Securities Laws</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company will comply with the
      Securities Act and the Exchange Act so as to permit the completion of the distribution of the Shares as contemplated by this Agreement<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">, </font>the Registration
      Statement, the General Disclosure Package and the Prospectus.&#160; Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Shares is required by the Securities Act to be delivered (whether
      physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(m)</font>&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Listing</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company will use its best efforts to list, subject to notice of
      issuance, the Shares on Nasdaq.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(n)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; If requested by the Representative, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representative an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">electronic Prospectus</font>&#8221; to be used by the Underwriters in connection with the offering and sale of the Shares.&#160; As used herein, the term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">electronic Prospectus</font>&#8221; means a form of Prospectus, and any amendment or supplement thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to the
      Representative, that may be transmitted electronically by the Representative and the other Underwriters to offerees and purchasers of the Shares; (ii) it shall disclose the same information as the paper Prospectus, except to the extent that graphic
      and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as
      appropriate; and (iii) it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representative, that will allow investors to store and have continuously ready access to the Prospectus at any future time, without
      charge to investors (other than any fee charged for subscription to the Internet as a whole and for on-line time).&#160; The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the
      Commission and in the Registration Statement at the time it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without
      charge, a paper copy of the Prospectus.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">23</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(o)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Agreement Not to Offer or Sell Additional Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font> During the period commencing
      on and including the date hereof and continuing through and including the 90<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Lock-up Period</font>&#8221;), the Company will not, without the prior written consent of the Representative (which consent may be withheld in its sole discretion), directly or indirectly:&#160; (i) sell,
      offer to sell, contract to sell or lend any shares of Common Stock or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#8220;put equivalent position&#8221; (as defined in Rule 16a-1(h) under the Exchange Act) or
      liquidate or decrease any &#8220;call equivalent position&#8221; (as defined in Rule 16a&#8209;1(b) under the Exchange Act) of any shares of Common Stock or Related Securities; (iii) pledge, hypothecate or grant any security interest in any shares of Common Stock or
      Related Securities; (iv) in any other way transfer or dispose of any shares of Common Stock or Related Securities; (v) enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership
      of any shares of Common Stock or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any shares of Common Stock or Related Securities; (vii) submit or file
      any registration statement under the Securities Act in respect of any shares of Common Stock or Related Securities (other than as contemplated by this Agreement with respect to the Shares and other than a registration statement on Form S-8 to
      register the offer and sale of securities to be issued pursuant to the Company&#8217;s 2023 Omnibus Incentive Plan or an inducement grant award, as permitted by Nasdaq Stock Market Rule 5635); (viii) effect a reverse stock split, recapitalization, share
      consolidation, reclassification or similar transaction affecting the outstanding shares of Common Stock; or (ix) publicly announce the intention to do any of the foregoing; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that the Company may (A) effect the transactions contemplated hereby, (B) issue shares of Common Stock or options to purchase shares of Common Stock, or issue shares of Common Stock upon exercise of options,
      pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to the grant of an inducement grant award, as permitted by Nasdaq
      Stock Market Rule 5635, but only if the recipients of such securities, to the extent that such recipients are directors and officers of the Company, have either already executed and delivered to the Representative a Lock-up Agreement or execute and
      deliver to the Representative a Lock-up Agreement in connection with such issuance, and (C) effect sales pursuant to the Open Market Sale Agreement<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup>, by and between the Company and Jefferies, dated November 27, 2024, provided that no such
      sales shall be made until the earlier of (x) the exercise in full by the Underwriters of their option to purchase the Optional Shares as<font style="font-size: 10pt; font-family: 'Times New Roman';"> provided in Section 2 and (y) the 31</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>
      day from the date of the Prospectus.&#160; For purposes of the foregoing, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Related Securities</font>&#8221; shall mean any options or warrants or other rights to acquire shares of
      Common Stock or any securities exchangeable or exercisable for or convertible into shares of Common Stock, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, shares of Common Stock.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">24</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(p)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Future Reports to the Representative.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160; </font>During the period of five years
      hereafter, the Company will furnish to the Representative, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate: (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report
      of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#8217;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>equity and cash flows for
      the year then ended and the opinion thereon of the Company&#8217;s independent public or certified public accountants; (ii) as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form 10-K, Quarterly Report on
      Form 10-Q, Current Report on Form 8-K or other report filed by the Company with the Commission, FINRA or any securities exchange; and (iii) as soon as available, copies of any report or communication of the Company furnished or made available
      generally to holders of its capital stock; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however,</font> that the requirements of this Section 3(p) shall be satisfied to the extent that such reports,
      statement, communications, financial statements or other documents are available on EDGAR.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(q)</font>&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Investment Limitation</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company shall not invest or otherwise use the
      proceeds received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(r)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Stabilization or Manipulation; Compliance with Regulation M</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company
      will not take, and will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Common Stock or any reference security with
      respect to the Common Stock, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(s)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Enforce Lock-Up Agreements</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; During the Lock-up Period, the Company will enforce
      all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Common Stock or Related Securities or any of the other actions restricted or prohibited under the
      terms of the form of Lock-up Agreement.&#160; In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &#8220;lock-up&#8221; agreements for the duration of the periods
      contemplated in such agreements, including, without limitation, &#8220;lock-up&#8221; agreements entered into by such persons listed in <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit B</u></font> pursuant to Section 6(j) hereof.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(t)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company to Provide Interim Financial Statements</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; Prior to the First Closing
      Date and each applicable Option Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period
      subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that
      the requirements of this Section 3(t) shall be satisfied to the extent that such unaudited interim financial statements are available on EDGAR.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(u)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">CSRC Filings</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; Beijing Continent Pharmaceuticals Co., Ltd, (d/b/a Gyre
      Pharmaceuticals) (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PRC Entity</font>&#8221;), a company formed under the laws of the PRC and an indirectly, majority-owned subsidiary of the Company, as the
      representative of the Company, shall, within the timeframe prescribed by CSRC, submit to the CSRC a report summarizing in a consolidated manner the overall information of all offerings made under the Registration Statement (excluding any Rule 462(b)
      Registration Statement) as required by the CSRC Filing Rules.&#160; In the event that the amount of the Shares the Company plans to issue exceeds the amount of the remaining unissued securities registered under the Registration Statement (excluding any
      Rule 462(b) Registration Statement) and the Company files any Rule 462(b) Registration Statement with SEC with respect to any of the Shares, the PRC Entity, as the representative of the Company, shall, within three business days following the
      completion of issuance and offering of the securities registered under such Rule 462(b) Registration Statement, complete the CSRC filing required with respect thereto under the CSRC Filing Rules (including submitting a CSRC filing report, a copy of
      the legal opinion of JunHe, the Company&#8217;s PRC counsel with respect to such filing, and other materials requested by the CSRC).</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">25</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Representative, on behalf of the several Underwriters, may, in its sole discretion, waive in writing the performance by the Company
      of any one or more of the foregoing covenants or extend the time for their performance.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Payment of Expenses.</font>&#160; The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder
        and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs), (ii) all fees and expenses of the registrar
        and transfer agent of the Common Stock, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares to the Underwriters, (iv) all fees and expenses of the Company&#8217;s counsel, independent public or
        certified public accountants and other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules,
        consents and certificates of experts), the General Disclosure Package, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, and all amendments and
        supplements thereto, and this Agreement, (vi) all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of)
        all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representative, preparing and printing a &#8220;Blue Sky Survey&#8221; or memorandum and a
        &#8220;Canadian wrapper&#8221;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii) the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with
        the rules and regulations of FINRA related to the Underwriters&#8217; participation in the offering and distribution of the Shares, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters, (viii) the
        costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or
        dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company,
        travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and one half of the cost of any aircraft chartered in connection with the road show, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that the prior written approval of the Company was obtained prior to the chartering of any such aircraft, (ix) the fees and expenses associated with listing the Shares on Nasdaq,
        and (x) all other fees, costs and expenses of the nature referred to in Item 14 of Part II of the Registration Statement; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that the Company
        shall not be responsible for any fees or expenses related to clauses (vi) and (vii) in excess of $30,000 in the aggregate, provided that the foregoing limitations shall not apply with respect to any FINRA filing fees pursuant to clause (vii).&#160;
        Except as provided in this <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 4 or in Section 7, Section 9 or Section 10 </font>hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of
        their counsel.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Covenant of the Underwriters.</font>&#160; Each Underwriter severally and not jointly covenants with the Company not to take any action that would result in the
        Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by
        the Company under Rule 433(d).</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Conditions of the Obligations of the Underwriters.</font>&#160; The respective obligations of the several Underwriters hereunder to purchase and pay for the
        Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 1 </font>hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then
        made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">26</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Comfort Letter</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; On the date hereof, the Representative shall have received from
      Grant Thornton Zhitong Certified Public Accountants LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representative, containing
      statements and information of the type ordinarily included in accountant&#8217;s &#8220;comfort letters&#8221; to underwriters, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited
      financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package, and each free writing prospectus, if any.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Compliance with Registration Requirements; No Stop Order; No Objection from FINRA.&#160; </font>For the period from and after the date of this Agreement and through and including
      the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">The Company shall have
        filed the Prospectus with the Commission (including the information previously omitted from the Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the
        Securities Act.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">No stop order
        suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">If a filing has been
        made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">No Material Adverse Change or Ratings Agency Change</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; For the period from and
      after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">in the judgment of the
        Representative there shall not have occurred any Material Adverse Change; and</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">there shall not have
        occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the
        Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating organization&#8221; as that term is used in Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Opinion of U.S. Counsel for the Company</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; On each of the First Closing Date and
      each Option Closing Date, the Representative shall have received the opinion and negative assurance letter of Gibson, Dunn &amp; Crutcher LLP, U.S. counsel for the Company, dated as of such date, in the form and substance reasonably satisfactory to
      the Representative.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Opinion of PRC Counsel for the Company.</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160; </font>On each of the First Closing Date and
      each Option Closing Date, the Representative shall have received the opinion of JunHe LLP, PRC counsel for the Company, dated as of such date, in the form and substance reasonably satisfactory to the Representative.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">27</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Opinion of IP Counsel for the Company.&#160; </font>On each of the First Closing Date and each Option Closing Date, the Representative shall have received a negative assurances
      letter and the written legal opinion of Rimon Law, P.C., intellectual property counsel for the Company, dated as of such date, in the form and substance reasonably satisfactory to the Representative.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Opinion of Counsel for the Underwriters</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; On each of the First Closing Date and
      each Option Closing Date, the Representative shall have received the opinion and negative assurance letter of Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Underwriters in connection with the offer and sale of the Shares, in the form and
      substance satisfactory to the Underwriters, dated as of such date.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(h)</font>&#160;&#160;&#160; &#160; &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Officers&#8217; Certificate</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; On each of the First Closing Date and each Option
      Closing Date, the Representative shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section 6(b)(ii)
      and further to the effect that:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">for the period from and
        including the date of this Agreement through and including such date, there has not occurred any Material Adverse Change;</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">the representations,
        warranties and covenants of the Company set forth in Section 1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">the Company has
        complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Bring-down Comfort Letter</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; On each of the First Closing Date and each Option
      Closing Date, the Representative shall have received from Grant Thornton Zhitong Certified Public Accountants LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the
      Representative, which letter shall:&#160; (i) reaffirm the statements made in the letter furnished by them pursuant to<font style="font-size: 10pt; font-family: 'Times New Roman';"> Section 6(a)</font>, except that the specified date referred to therein
      for the carrying out of procedures shall be no more than two business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii) cover certain financial information contained in the Prospectus.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Lock-Up Agreements.</font>&#160; On or prior to the date hereof, the Company shall have furnished to the Representative an agreement in the form of <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit A</u></font> hereto from each of the persons listed on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit B</u></font> hereto, and each such agreement shall be in full force and
      effect on each of the First Closing Date and each Option Closing Date.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Rule 462(b) Registration Statement</font>.&#160; In the event that a Rule 462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such
      Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(l)</font>&#160;&#160;&#160; &#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">CFO Certificate</font>. On the date of this Agreement and on the First Closing Date or the applicable Option Closing Date, as the case may be, the Company shall have furnished
      to the Representative a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain financial data contained in the General Disclosure Package and the
      Prospectus, providing &#8220;management comfort&#8221; with respect to such information, in form and substance reasonably satisfactory to the Representative.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">28</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Additional Documents</font>.&#160; On or before each of the First Closing Date and each Option Closing Date, the Representative and counsel for the Underwriters shall have received
      such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Shares as contemplated herein, or in order to evidence the accuracy of any of the representations and
      warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Shares as contemplated herein and in connection with the other
      transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representative and counsel for the Underwriters.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If any condition specified in this <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 6 </font>is not satisfied
      when and as required to be satisfied and is not waived by the Representative, this Agreement may be terminated by the Representative by notice from the Representative to the Company at any time on or prior to the First Closing Date and, with respect
      to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that<font style="font-size: 10pt; font-family: 'Times New Roman';">
        Section 4</font>,<font style="font-size: 10pt; font-family: 'Times New Roman';"> Section 7, Section 9 and Section 10 </font>shall at all times be effective and shall survive such termination.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Reimbursement of Underwriters&#8217; Expenses</font>.&#160; If this Agreement is terminated by the Representative pursuant to Section 6, Section 11 <font style="font-size: 10pt; font-family: 'Times New Roman';">or Section 12,</font> or if the sale to the Underwriters of the Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the Company
        to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representative and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally,
        upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representative and the Underwriters in connection with the proposed purchase and the offering and sale of the Shares, including, but not limited to, fees and
        disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Effectiveness of this Agreement</font>.&#160; This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Indemnification</font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Indemnification of the Underwriters</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The Company agrees to indemnify and hold
      harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or
      expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the
      laws or regulations of foreign jurisdictions where the Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such
      loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any
      amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material
      fact included in any preliminary prospectus, the General Disclosure Package, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Materials
      or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not
      misleading; or (iii) any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to
      in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i) or (ii) above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any
      and all expenses (including the reasonable fees and disbursements of counsel) as such expenses are reasonably incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating,
      defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that the foregoing indemnity
      agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and
      in conformity with information relating to any Underwriter furnished to the Company by the Representative in writing expressly for use in the Registration Statement, any preliminary prospectus, the General Disclosure Package, any such free writing
      prospectus, any Marketing Materials or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in Section 9(b) below.&#160; The indemnity agreement set
      forth in this Section 9(a) shall be in addition to any liabilities that the Company may otherwise have.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">29</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Indemnification of the Company, its Directors and Officers</font>.&#160; Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its
      directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred,
      to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where
      the Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or
      actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged
      omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the
      General Disclosure Package, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act or the Prospectus (or any such amendment or supplement) or the omission or
      alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement
      or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the General Disclosure Package, such free writing prospectus or the Prospectus (or any such amendment or supplement), in
      reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representative in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for
      any and all expenses (including the reasonable fees and disbursements of counsel) as such expenses are reasonably incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling,
      compromising or paying any such loss, claim, damage, liability, expense or action.&#160; The Company hereby acknowledges that the only information that the Representative has furnished to the Company expressly for use in the Registration Statement, any
      preliminary prospectus, the General Disclosure Package, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement to the foregoing)
      are the statements set forth in<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>the first sentence of the third paragraph, the first two sentences of the fifth paragraph and the first sentence of the eleventh
      paragraph under the caption &#8220;Underwriting&#8221; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement.&#160; The indemnity agreement set forth in this <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 9(b) </font>shall


      be in addition to any liabilities that each Underwriter may otherwise have.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">30</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Notifications and Other Indemnification Procedures</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; Promptly after receipt by
      an indemnified party under this <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 9 </font>of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an
      indemnifying party under this Section 9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any
      indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this
      indemnity agreement.&#160; In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the
      extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof
      with counsel reasonably satisfactory to such indemnified party; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that if the defendants in any such action include both the indemnified party
      and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be
      legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal
      defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties.&#160; Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election to so assume the
      defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section 9 for any legal or other expenses subsequently incurred by such indemnified party in
      connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the
      fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by
      the Representative (in the case of counsel for the indemnified parties referred to in Section 9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section 9(b) above)), (ii) the indemnifying party shall not
      have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for
      the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Settlements</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; The indemnifying party under this Section 9 shall not be liable
      for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim,
      damage, liability or expense by reason of such settlement or judgment.&#160; Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of
      counsel as contemplated by Section 9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such
      indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.&#160; No indemnifying party shall, without the prior written
      consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was
      or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or
      proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">31</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Contribution</font>.&#160; If the indemnification provided for in Section 9 is for any reason held to be unavailable to or otherwise insufficient to hold
        harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a
        result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the
        offering of the Shares pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)
        above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other
        relevant equitable considerations.&#160; The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same
        respective proportions as the total proceeds from the offering of the Shares pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each
        case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Shares as set forth on such cover.&#160; The relative fault of the Company, on the one hand, and the Underwriters, on the other hand,
        shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one
        hand, or the Underwriters, on the other hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be
      deemed to include, subject to the limitations set forth in Section 9(c), any reasonable and reasonably documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.&#160;
      The provisions set forth in Section 9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 10; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however,</font> that no additional notice shall be required with respect to any action for which notice has been given under Section 9(c) for purposes of indemnification.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 10 were
      determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section 10.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">32</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding the provisions of this Section 10, no Underwriter shall be required to contribute any amount in excess of the
      underwriting discounts and commissions received by such Underwriter in connection with the Shares underwritten by it and distributed to the public.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
      Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.&#160; The Underwriters&#8217; obligations to contribute pursuant to this Section 10 are several, and not joint, in proportion to their
      respective underwriting commitments as set forth opposite their respective names on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule A</u></font>.&#160; For purposes of this Section 10, each affiliate, director, officer,
      employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company,
      each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Default of One or More of the Several Underwriters</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font>&#160; If, on
        the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such
        defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Shares to be purchased on such date, the Representative may make arrangements satisfactory to the Company for the
        purchase of such Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm Shares
        set forth opposite their respective names on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule A</u></font> bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting Underwriters,
        or in such other proportions as may be specified by the Representative with the consent of the non-defaulting Underwriters, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such
        date.&#160; If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Shares and the aggregate number of Shares with respect to which such default occurs exceeds 10% of the aggregate
        number of Shares to be purchased on such date, and arrangements satisfactory to the Representative and the Company for the purchase of such Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of
        any party to any other party except that the provisions of <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 4, Section 7, Section 9 and Section 10 </font>shall at all times be effective and shall survive such termination.&#160;
        In any such case either the Representative or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required
        changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">As used in this Agreement, the term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Underwriter</font>&#8221;
      shall be deemed to include any person substituted for a defaulting Underwriter under this Section 11.&#160; Any action taken under this Section 11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter
      under this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Termination of this Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font>&#160; Prior to the purchase of
        the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representative by notice given to the Company if at any time: (i) trading or quotation in any of the Company&#8217;s securities shall have been
        suspended or limited by the Commission or by Nasdaq, or trading in securities generally on either Nasdaq or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock
        exchanges; (ii) a general banking moratorium shall have been declared by any of federal or New York authorities; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any
        change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or international political, financial or economic conditions, as in the judgment
        of the Representative is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the General Disclosure Package or the Prospectus or to enforce contracts for the sale of securities; (iv) in
        the judgment of the Representative there shall have occurred any Material Adverse Change; or (v) the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the
        Representative may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured.&#160; Any termination pursuant to this Section 12 shall be without liability on the
        part of (a) the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representative and the Underwriters pursuant to<font style="font-size: 10pt; font-family: 'Times New Roman';"> Section 4 or
          Section 7 </font>hereof or (b) any Underwriter to the Company; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however,</font> that the provisions of <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 9 and Section 10 </font>shall at all times be effective and shall survive such termination.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">33</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">No Advisory or Fiduciary Relationship.&#160; </font>The Company acknowledges and agrees that (a) the purchase and sale of the Shares pursuant to this Agreement,
        including the determination of the public offering price of the Shares and any related discounts and commissions, is an arm&#8217;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)
        in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, or its creditors,
        employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether
        such Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement,
        (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided any legal, accounting, regulatory or tax
        advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Representations and Indemnities to Survive Delivery</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font>&#160; The
        respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of
        any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive
        delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Notices</font>.&#160; All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as
        follows:</font></div>
    <div>&#160;
      <table cellspacing="0" cellpadding="0" border="0" id="z3f46b4e296f84012b9b3a370be0d027f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If to the Representative:</div>
            </td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Jefferies LLC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">520 Madison Avenue</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">New York, New York 10022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Facsimile:&#160; (646) 619-4437</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Attention:&#160; General Counsel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 62%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">with a copy to:</div>
            </td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Wilmer Cutler Pickering Hale and Dorr LLP</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">7 World Trade Center</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">250 Greenwich Street</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">New York, NY 10007</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Facsimile: (212) 230-8888</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">34</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Attention: Lisa Firenze</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 62%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If to the Company:</div>
            </td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Gyre Therapeutics, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">12770 High Bluff Drive</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Suite 150</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">San Diego, CA 92130</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Attention: Chief Executive Officer; Chief Financial Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 62%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">with a copy to:</div>
            </td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Gibson, Dunn &amp; Crutcher LLP</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">One Embarcadero Center</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Suite 2600</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">San Francisco, CA 94111</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Facsimile: (415) 374-8456</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 62%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Attention: Ryan A. Murr; Branden C. Berns</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Any party hereto may change the address for receipt of communications by giving written notice to the others.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 16.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Successors</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font>&#160; This Agreement will inure to the benefit of
        and be binding upon the parties hereto, including any substitute Underwriters pursuant to Section 11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in<font style="font-size: 10pt; font-family: 'Times New Roman';"> Section 9 and Section 10</font>, and in each case their respective successors, and no other person will have any right or obligation hereunder.&#160; The term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">successors</font>&#8221; shall not include any purchaser of the Shares as such from any of the Underwriters merely by reason of such purchase.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 17.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Partial Unenforceability</font>.&#160; The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity
        or enforceability of any other section, paragraph or provision hereof.&#160; If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
        only such minor changes) as are necessary to make it valid and enforceable.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 18.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Recognition of the U.S. Special Resolution Regimes.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that any Underwriter
      that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as
      the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that any Underwriter
      that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be
      exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">For purposes of this Agreement, (A) &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">BHC Act Affiliate</font>&#8221; has the
      meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Covered Entity</font>&#8221; means any of the following:
      (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#8220;covered FSI&#8221; as that
      term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (C) &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Default Right</font>&#8221; has the meaning assigned to that term in, and shall be
      interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">U.S. Special Resolution Regime</font>&#8221; means each of (i) the Federal Deposit
      Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">35</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 19.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Governing Law Provisions</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font>&#160; This Agreement shall be governed
        by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.&#160; Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions
        contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the
        City of New York (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Specified Courts</font>&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in
        regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.&#160; Service of any process, summons, notice or document by mail to such party&#8217;s address
        set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.&#160; The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other
        proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 20.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Judgment Currency&#894; Payments. </font> The obligation of the Company in respect of any sum due to any Underwriter under this Agreement shall, notwithstanding
        any judgment in a currency other than U.S. dollars (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Judgment Currency</font>&#8221;), not be discharged until the first business day following receipt by the
        applicable Underwriter of any sum adjudged to be so due in the Judgment Currency on which (and only to the extent that) the applicable Underwriter may in accordance with normal banking procedures purchase U.S. dollars with the Judgment Currency&#894; if
        the U.S. dollars so purchased are less than the sum originally due to the applicable Underwriter hereunder, the Company agrees, as a separate obligation and notwithstanding any such judgment, to indemnify the applicable Underwriter against such
        loss in respect of any sum due to the applicable Underwriter from the Company. If the U.S. dollars so purchased are greater than the sum originally due to the applicable Underwriter hereunder, the applicable Underwriter shall pay to the Company an
        amount equal to the excess of the U.S. dollars so purchased over the sum originally due to the applicable Underwriter hereunder. All payments made or deemed to be made by the Company under this Agreement, if any, to the Underwriters, their
        respective affiliates, and their affiliates&#8217; respective partners, members, directors, officers, employees and agents or to any person controlling an Underwriter within the meaning of the Securities Act or the Exchange Act or that is controlled by
        or is under common control with an Underwriter, will be made without withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income or
        similar taxes) imposed or levied by or on behalf of the PRC, Hong Kong or any political subdivision or any taxing authority thereof or therein unless the Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or
        other governmental charges. In such event, the Company will pay such additional amounts as will result, after such withholding or deduction, in the receipt by any of the Underwriters, their respective affiliates, and their affiliates&#8217; respective
        partners, members, directors, officers, employees and agents or to any person controlling such Underwriter within the meaning of the Securities Act or the Exchange Act or that is controlled by or is under common control with such Underwriter as the
        case may be, of the amounts that would otherwise have been receivable in respect thereof.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">36</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Section 21.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">General Provisions.</font>&#160; This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and
        all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.&#160; This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the
        signatures thereto and hereto were upon the same instrument.&#160; Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the
        Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
        purposes.&#160; This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.&#160; The
        section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
      negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of <font style="font-size: 10pt; font-family: 'Times New Roman';">Section 9 </font>and the contribution provisions of<font style="font-size: 10pt; font-family: 'Times New Roman';"> Section 10</font>, and is fully informed regarding said provisions.&#160; Each of the parties hereto further acknowledges that the provisions of <font style="font-size: 10pt; font-family: 'Times New Roman';">Section


        9 and Section 10 </font>hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate disclosure has been made in the Registration Statement, any
      preliminary prospectus, the General Disclosure Package, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">37</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies
      hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</div>
    <div>&#160;
      <table cellspacing="0" cellpadding="0" border="0" id="zcc9fbdedee4548089ae531bd87cae9c2" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2" rowspan="1">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2" rowspan="1">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">GYRE THERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;" colspan="1">By:</td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Han Ying</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Name: Han Ying</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Title: Chief Executive Officer</div>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representative in New York, New York as of the date first
      above written.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">JEFFERIES LLC</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Acting individually and as Representative</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">of the several Underwriters named in</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">the attached <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule A</u></font>.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">JEFFERIES LLC</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z234035714d77459c8d582423126afaa5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Bryan Czyzewski</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Name: Bryan Czyzewski</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Title: Managing Director</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">38</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Schedule A</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" align="left" style="width: 70%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="zfae3739a9d8340268b305c46ce1e24d6" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: top; width: 58%;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Underwriters</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: top;" colspan="2">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div>
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Firm Shares to </div>
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">be Purchased</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 58%; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Jefferies LLC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">2,000,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 58%; padding-bottom: 2px;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">H.C. Wainwright &amp; Co., LLC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">222,222</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 58%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; margin-left: 9pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Total<br>
              </font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">2,222,222</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="clear: both;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Schedule B</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Free Writing Prospectuses Included in the General Disclosure Package</u></div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">None.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Schedule B-1</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Pricing Terms</u></div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd7a37abdb5cd4fdc8ab15b8929c234b2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company is selling 2,222,222 Shares.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z87293eabeb8f415d805cf5f496a23673" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The offering price to the public shall be $9.00 per Share.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z1ac067f7d5ee4819b733f83c58180508" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The underwriting discount shall be 6% of the offering price to the public.</div>
          </td>
        </tr>

    </table>
    <br>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%A-%%-->
    <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit A</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Form of Lock-up Agreement</u></div>
    <div>&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">[</font>&#9679;]<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">,
        2025</font></div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Jefferies </font>LLC</div>
    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">As Representative of the Several Underwriters</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">c/o Jefferies </font>LLC</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">520 Madison Avenue</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">New York, New York 10022</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z5db9e7c03b5542de8455a9d99a96ece4" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">RE:</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Gyre Therapeutics, Inc. (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company</font>&#8221;)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Ladies &amp; Gentlemen:</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">The undersigned is an owner of shares of common stock, par value $0.001 per share, of the
        Company (&#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">&#8221;) or of securities convertible into or
        exchangeable or exercisable for Shares.&#160; The Company proposes to conduct an offering of Shares (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Offering</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">&#8221;) for which Jefferies </font>LLC<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> (&#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Jefferies</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">&#8221;) will act as the representative of the underwriters.&#160; The undersigned recognizes that the Offering will benefit
        each of the Company and the undersigned.&#160; The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent
        date, in entering into an underwriting agreement (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Underwriting Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">&#8221;) and other underwriting arrangements with the Company with respect to the Offering.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this agreement.&#160; Those definitions
      are a part of this agreement.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby
      agrees that, during the Lock-up Period, the undersigned will not (and will cause any Family Member not to), subject to the exceptions set forth in this letter agreement, without the prior written consent of Jefferies, which may withhold its consent
      in its sole discretion:</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z36138686ca0f4663842b3fc220e24715" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the
              undersigned or such Family Member,</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf098a976385a4d1cb724cef8be2e988a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">enter into any Swap,</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0acd4386dd4f4a1fbe7cf11307528a8f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed
              a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zdc8efd5a253c41f08a8f7e84a292f2bf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">publicly announce any intention to do any of the foregoing.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-1</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing will not apply to the registration of the offer and sale of the Shares and/or Related Securities, and the sale of the Shares and/or Related Securities to the
      underwriters, in each case as contemplated by the Underwriting Agreement.&#160; In addition, the foregoing restrictions shall not apply to (a) the transfer of Shares or Related Securities by gift, or by will or intestate succession to a Family Member or
      to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member, (b) pursuant to a court order in respect of, or by operation of law as a result of, a divorce, (c) if the undersigned is a non-individual,
      transfer of Shares or Related Securities to any affiliate (as such term is defined in Rule 405 of the Securities Act), limited partners, general partners, limited liability company members, trust beneficiaries or stockholders of the undersigned, or,
      if, in any case, such transfer is not for value or (d)&#8239;transactions relating to Shares acquired in open market transactions after the completion of the Offering; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided,


        however</font>, that:</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z36a253e6edc042249147c45744d1ff29" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">in the cases described in (a), (b), and (c) above, each transferee executes and delivers to Jefferies an agreement in form and substance satisfactory to Jefferies stating that such
              transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any
              other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto);</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zfa9155c01fb24de5a828a2dcc34e6fae" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">in the case described in (b) above, prior to the expiration of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee,
              transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection with such transfer; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z900157628e7742bba54b69a90efcac86" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">in the cases described in (a), (c) and (d) above, prior to the expiration of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party to the transfer
              (donor, donee, transferor or transferee) shall be made voluntarily reporting a reduction in beneficial ownership of Shares in connection with such transfer, and any public disclosure or filing under the Exchange Act by any party to the
              transfer (donor, donee, transferor or transferee) required to be made reporting a reduction in beneficial ownership of Shares in connection with such transfer shall include a statement describing the circumstances of such transfer and, in the
              cases described in (a) and (c) above, that the transferee has agreed to be bound by the terms of this letter.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to
      any Company-directed Shares the undersigned may purchase or otherwise receive in the Offering (including pursuant to a directed share program).</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of
      Shares or Related Securities held by the undersigned and the undersigned's Family Members, if any, except in compliance with the foregoing restrictions.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Furthermore, notwithstanding the restrictions imposed by this letter agreement, the undersigned may (i) transfer Shares to the Company upon the exercise of
      options or warrants or the vesting of restricted stock units during the Lock-up Period to cover tax withholding obligations in connection with such exercise or vesting or for the primary purpose of paying the exercise price of options or warrants to
      acquire Shares, in each case pursuant to a stock option, stock bonus or other stock plan or arrangement or warrants existing as of the date hereof or described in the Prospectus (as defined in the Underwriting Agreement) and any Shares acquired upon
      such exercise or vesting shall remain subject to this letter agreement; provided that if the undersigned is required to file a report under the Exchange Act related thereto, such report shall include a statement to the effect that the filing relates
      to the &#8220;net&#8221; or &#8220;cashless&#8221; exercise of options to purchase shares of common stock for the purpose of exercising such options including, if applicable, the payment of taxes due as a result of the exercise of options or vesting of restricted stock
      units, (ii) establish a trading plan pursuant to Rule 10b5-1 under the Exchange Act (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">10b5-1 Plan</font>&#8221;), provided that no sales or other dispositions of Shares or
      Related Securities may occur under such plan during the Lock-up Period and no public announcement or filing under the Exchange Act, shall be voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such 10b5-1
      Plan during the Lock-up Period, and any public announcement or filing under the Exchange Act required of the undersigned or the Company regarding the establishment of such 10b5-1 Plan during the Lock-up Period shall include a statement to the effect
      that no transfer of Shares may be made under such 10b5-1 Plan during the Lock-up Period, (iii) transfer or dispose of Shares or Related Securities pursuant to a 10b5-1 Plan that has been entered into by the undersigned prior to the date of this
      letter agreement; provided, that, no amendments or other modifications are made to such 10b5-1 Plan during the Lock-Up Period, no public announcement or filing under the Exchange Act shall be voluntarily made by or on behalf of the undersigned or the
      Company regarding such sale or transfer and, to the extent a public announcement or filing under the Exchange Act, if any, is required to be made by or on behalf of the undersigned or the Company regarding such sale or transfer, such announcement or
      filing shall include a statement to the effect that the sale or transfer was made pursuant to a 10b5-1 Plan, or (iv) transfer the undersigned&#8217;s Shares or Related Securities pursuant to a bona fide third-party offer for all outstanding voting stock of
      the Company, whether pursuant to a merger, tender offer or otherwise, to a third party or group of third parties, provided that in the event that such merger, tender offer or other transaction is not consummated, such Shares or Related Securities
      held by the undersigned shall remain subject to the restrictions on transfer set forth herein.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of
      any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
      or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares.&#160; The undersigned will not, and will cause any Family Member not to take,
      directly or indirectly, any such action.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned acknowledges and agrees that the underwriters have not provided any recommendation or investment advice nor have the underwriters solicited
      any action from the undersigned with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.&#160; The undersigned further acknowledges and agrees
      that, although the Representatives and underwriters may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to the undersigned in connection with the Offering, the Representatives and the other underwriters are
      not making a recommendation to the undersigned to enter into this letter agreement and nothing set forth in such disclosures is intended to suggest that the Representatives or any underwriter is making such a recommendation.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other factors.&#160; The Offering will only be made
      pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">This letter agreement shall automatically terminate and be of no further effect upon the earliest to occur, if any, of (i) Jefferies, on behalf of the
      underwriters, or the Company, advising the other party in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Offering, (ii)&#8239;the termination of the Underwriting Agreement before the sale of
      the Shares to the underwriters, (iii) the Registration Statement (as defined in the Underwriting Agreement) filed with the Securities and Exchange Commission with respect to the Offering is withdrawn, and (iv) June 30, 2025, in the event that the
      Underwriting Agreement has not been executed by such date (provided that the Company may by written notice to the undersigned prior to June 30, 2025, extend such date for a period of up to three additional months).</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement.&#160; This letter
      agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">This letter agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act
      of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York.</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">[Remainder of page intentionally left blank]</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">&#160;&#160;&#160; <br>
    </div>
    <div>
      <hr noshade="noshade" align="left" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto 0px 0px; height: 2px; width: 40%; color: #000000; text-align: left;"></div>
    <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Signature</div>
    <div>&#160;</div>
    <div style="text-align: left;"><br>
    </div>
    <div>
      <hr noshade="noshade" align="left" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto 0px 0px; height: 2px; width: 35%; color: #000000; text-align: left;"></div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Printed Name of Person Signing</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Indicate capacity of person signing if</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">signing as custodian or trustee, or on behalf</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">of an entity)</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Annex A</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Certain Defined Terms</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Used in Lock-up Agreement</u></div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Call Equivalent Position</font>&#8221;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>shall have the meaning set forth in Rule 16a-1(b) under the Exchange Act.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exchange Act</font>&#8221;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>shall mean the Securities Exchange Act of 1934, as amended.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Family Member</font>&#8221; shall mean the spouse of the
      undersigned, an immediate family member of the undersigned or an immediate family member of the undersigned's spouse, in each case living in the undersigned's household or whose principal residence is the undersigned's household (regardless of
      whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise).&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Immediate family member</font>&#8221; as used above shall have the meaning set forth in Rule 16a-1(e) under the Exchange Act.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Lock-up Period</font>&#8221; shall mean the period
      beginning on the date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus (as defined in the Underwriting Agreement).</div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Put Equivalent Position</font>&#8221; shall have the
      meaning set forth in Rule 16a-1(h) under the Exchange Act.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Related Securities</font>&#8221; shall mean any options
      or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Securities Act</font>&#8221; shall mean the Securities
      Act of 1933, as amended.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Sell or Offer to Sell</font>&#8221; shall mean to:</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0784959b839347f98cc6e90881aedc4a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">sell, offer to sell, contract to sell or lend,</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z1ab03d02b8ed4a8480c0f32c51e21e24" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call Equivalent Position</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z1259b38d03164c1da4ce433e22e8336f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">pledge, hypothecate or grant any security interest in, or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z223763c4d5b641bc82aa046610f870bc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">in any other way transfer or dispose of,</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 18pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">in each case whether effected directly or indirectly.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Swap</font>&#8221; shall mean any swap, hedge or similar
      arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this lock-up agreement.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%B-%%-->
    <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit B</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Directors, Officers and Others</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Signing Lock-up Agreement</div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 35%; color: #000000; text-align: center;"> </div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Directors:</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Ping Zhang</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Gordon G. Carmichael</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Thomas Eastling</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">David M. Epstein</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Rodney L. Nussbaum</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Renate Parry, Ph.D.</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Officers:</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Han Ying</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Songjiang Ma</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Ruoyu Chen</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Weiguo Ye</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Others:</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">GNI Group Ltd. (GNI Japan)</div>
    <div>&#160;</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">GNI USA, Inc.</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div style="text-align: center;"> <font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">B-1</font></div>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ef20049643_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;">
  </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"> <font style="font-weight: bold; font-size: 10pt;">Exhibit 5.1</font><font style="font-size: 10pt;"><br>
    </font></div>
  <div>
    <div style="text-align: right;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      <div style="text-align: left;"><img width="170" height="16" src="image0.jpg"></div>
    </div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Client: 21582-00008</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">May 23, 2025</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Gyre Therapeutics, Inc.</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">12770 High Bluff Drive, Suite 150</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">San Diego, CA 92130</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zec42ff18831c431e9edec7dceee8ab23" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Re:</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">Gyre Therapeutics, Inc.</div>
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Registration Statement on Form S-3 (File No. 333-283237)</div>
            </div>
          </td>
        </tr>

    </table>
    <br>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We have examined the Registration Statement on Form S-3 (File No. 333-283237) (the &#8220;<font style="font-family: 'Times New Roman';"><u>Registration
          Statement</u></font>&#8221;) of Gyre Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), filed with the Securities and Exchange Commission (the &#8220;<font style="font-family: 'Times New Roman';"><u>Commission</u></font>&#8221;) pursuant to the Securities Act of 1933, as amended (the &#8220;<font style="font-family: 'Times New Roman';"><u>Securities Act</u></font>&#8221;), in connection with the offering by the Company
      of up to 2,555,555 shares (the &#8220;<font style="font-family: 'Times New Roman';"><u>Shares</u></font>&#8221;) of common stock, par value $0.001 per share (the &#8220;<font style="font-family: 'Times New Roman';"><u>Common Stock</u></font>&#8221;)
      pursuant to the Underwriting Agreement, dated as of May 22, 2025, among the Company and the representative of the underwriters named therein.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as
      being true and complete copies of the originals, of specimen Common Stock certificates and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or
      advisable to enable us to render the opinions set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all
      documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion
      that the Shares, when issued against payment therefor as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the
      caption &#8220;<font style="font-family: 'Times New Roman';"><u>Legal Matters</u></font>&#8221; in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the
      category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Very truly yours,</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">/s/ Gibson, Dunn &amp; Crutcher LLP</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
  </div>
  <div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Gibson, Dunn &amp; Crutcher LLP</font><font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
      </font><font style="font-size: 10pt;">One Embarcadero Center Suite 2600&#160; |&#160; San Francisco, CA 94111-3715&#160; |&#160; T: 415.393.8200&#160; |&#160; F: 415.393.8306&#160; |&#160; gibsondunn.com</font></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <font style="font-size: 10pt;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>gyre-20250522.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<xs:schema targetNamespace="http://ir.catalystbiosciences.com/20250522" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:gyre="http://ir.catalystbiosciences.com/20250522" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="gyre-20250522_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gyre-20250522_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>gyre-20250522_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>gyre-20250522_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="gyre-20250522.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "D!GT# 2(  A$! Q$!_\0
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MU;XD>'_'.GVGVK[1X6\4_#KP-::#JGVBSN+6+[?<>"=#\'>)X_L4\T>HVO\
M9GB/3M]Y:6Z7OVO3VN[&Z\.^/7[$'[3/[-]M>ZS\2?AKJ \&VFH:C9+\0/#%
MS:>*O!DEM9:K8:/9ZMJ&I:-+<7?A+3_$-WJVF+X;C\=Z=X5U75Y+T6<&F#4K
M34;&S^3J_2(</^&G'& CCZ.2\&<3X"M]9IT\PP^ RC,8PJ5E%8J-'&T:52IA
ML5?D]LZ56EB:52,')PJPBX_GT\]\0^#<;+ U<VXMX=QM+ZO4G@:^-S7 2E3I
M.3PSJX.K4IT\1AK<_LE4I5,/4IRFHJ5.<D_W4\$_\%QO']AI5Q#\1_@#X/\
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M.I3E)1C&,Z4I2E)VC&,51;<FVDDE=O1'ZY_\/L/VJ?\ H0/V?O\ PE?B-_\
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M]UJ&C^&[.&\T9+G0;CQ+I&IV^IQ_/W_#]3_JUO\ \S=_^**M#]J?_@CYX_\
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M?QY_9NKV&D7WV3PM;V7A7Q1X<U7[5HGQ,MKF/97X^?%/_@I]^V7\4?[=L_\
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MVG3?'_C/^V?&\'D_\6S\"Q6OB7QXGF_V'/\ \36P^W6.D>$]VD>(++Q!8_\
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MGTG4YM"^'FM:'+J&FRNUG>R:-K.K:4]S#(VG:G?VAANI=#_AR?\ M4_]#_\
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MG[_PE?B-_P#/6K\?**_1?^(*>%7_ $0^2?\ @JM_\N/@?^(O>)G_ $66<?\
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M_P#/6H_X?8?M4_\ 0@?L_?\ A*_$;_YZU?CY17[+_P 04\*O^B'R3_P56_\
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M?\*S^./Q!\(^3]N_MO\ X3KP[X<^(O\ :'F?8_[-_LK_ (1]_A=_8_V39?\
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M1U:.Z\2F]TFXN]1;7+C3_'\4'BC6I-,&GW6G^%]5T/4XXM6M=*U_PUX;T?\
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M1S>'P&&YWIB<;[*JE55.K#"TH3K5(2E[&E6Y_P#8\_X)_?"+]DO2AJ*QZ?\
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MX3;P3]KFFN[_ ,'W]W-!#=VDT]WJO@S5;NWT+7;B]MKWPUXE\5?QTUV'P_\
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MCF@DFM+_ $^_M)K?4=)U;3KB[TK6=*N[+5M)O;W3;VUNIO\ 03PO\6^'/%#
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M> %LKG2?%%QIOQ U_1K;\&_V:?A!<_'SX]_"GX10P:A-:>-/&&F67B%M)O\
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M*O\ U8WPIK\N\:_^35<<?]B2K_Z>HGZ1X0?\G,X-_P"QQ3_]-5C^H6BBBO\
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M2GA_K&18K&8G+Z^(HJ4I9?BZ%54X1QL.7]W1Q7-%8;$)NE*M?#U'3JRH*O\
M+U%%%?7GRI^B7_!/#]M75?V5_BC9Z%XO\0:A'^S_ ..-0D3X@Z,NG7.O1^'=
M5ET]K/2?B!H&G6]S#=V&H6%W#I5KXNDTJ'4KG7/!D%S ?#WB'7]%\&KIG]<V
MDZOI6OZ5IFNZ%J>GZUH>M:?9:MHVLZ3>VVI:5JVE:E;1WFG:GIFHV<DUI?Z?
M?VDT-U97MK-+;75M+'/!(\3JQ_@'K]D_^"6O[>&E?!+5;GX#_&KQ/J%E\+/%
M6H6LGP^\1:M?6Q\,?"SQ/=W-])JUEJ;7%O\ :]'\'^-KN]MKF]U,:F/#WA'Q
M#:2:W?:396/BKQEXLTO^3OI$>"[XCP^(X[X7PTI9_@</#^V<IPN'C*IGF$HR
MY?KN'C2BJE7-L%1E^]A+VD\=@:$*-"V)PU&CB_Z>\!O%U9!B*'!?$F(4<DQF
M(G_9.9XFO)0R?%55=8.O*I)PIY9BZT?W<H^SA@\;7G5K7P^(K5L+_3K1117\
M ']Q!1110 4444 %?S]_\%U/^;6_^ZW?^\BK^@2OP;_X+E^%M>N_"O[.GC:W
ML/,\,>'_ !!\2/"VKZG]JLT^R:]XQT[P?JWARQ^Q/<+J%Q_:.G^!O%-Q]JM;
M2:SM/[+\J_N+6>]TZ.[_ &GZ/-6G1\8N#9U:D*47//*2E4E&$74K<-9S1HTT
MY-)SK5JD*5*"?-4J3A""<I)/\B\=Z=2KX4<61I4YU)*&35'&G&4Y*G1XARFK
M5J-13:A2I0G5J2^&%.$IR:C%M?SMU_7M_P $J-)TK3?V&?A#>:=IFGV%WK^H
M?$G5M=NK*RMK6YUK58?B=XOT*'4]6G@CCEU+4(M#T71M&CO;QIKE-*TG3-.6
M06EA:PQ?R$U_8-_P2T_Y,1^!?_=3O_5Q_$*OZG^EG.4?#?)U&4HJ?&F6QFDV
ME.*R3B*:C)+245.$)V=US1C+>*:_FOZ+\8R\0,U<HIN'".82@VDW&3SC(8.4
M6_AER2E&ZL^64H[-H_0*BBBO\[S^\0HHHH **** "BBB@ HHHH **** "OX>
M/VL_^3J?VF/^S@?C+_ZL;Q)7]P]?P\?M9_\ )U/[3'_9P/QE_P#5C>)*_KWZ
M(?\ R4?&'_8DP/\ ZGL_E?Z4_P#R(.%?^QQC?_4)'S]1117]YG\3G[!_\$3_
M /DZGQ__ -F_>*O_ %8WPIK^H6OY>O\ @B?_ ,G4^/\ _LW[Q5_ZL;X4U_4+
M7^:WTH/^3JXO_L29-_Z9J'^A'T<?^39X7_L<9M_Z=IA1117\\'[P%%%% !11
M10 5^;O_  4<_8F_X:L^&]IX@^'^E^'X/CKX!S/X;U*_7[!>>,_"L<6HS:A\
M,[C6S>VFGVGVO4+N/6_"U_XBAO=.TC7K>ZTU+OPQI?C'Q/X@@_2*BO?X8XES
M?A#/<NXBR/$?5\QRVNJU)R4I4:T&G"MA<33C*#JX7%493H8BDIP<Z4Y<DX3Y
M9Q\3B/A[*^*LEQ^0YS0]O@,PHNE54;1JTIIJ='$X><HS5+$X:K&%:A4<9*-2
M$>:$X<T)?Y^]%?KG_P %;?V4[;X-_%VS^-?@O3=03P'\;]0UO4_$K23ZKJEM
MH?Q=EOKK6?$D;WEQIHM-'T_QM:7H\1^'M)N=>U*^N=5T[X@+I=EI/AK1=+TZ
MU_(RO]:N#>*\NXVX:RGB;*^987-,/[5T9RC*KA,33E*CB\'6<='5PN)IU*,I
M)*,^15(+DG%O_+WBSAG'\'\0YGP[F5I8G+<1[-5H1E&EBJ%2,:N&Q=%2U5/$
MX>=.K&+O*',Z<O?A)(K] OV _P!MKQ5^RC\2-/T35M4^U_ KQSX@TR#XC^']
M1;4KBS\-?:Y;339_B9X<ATVRU34+7Q!X>T](YM7L-,TV[_X3;0=.3P_>VC:I
M:>%-;\-?G[179Q'P[E/%>2X_(,\PD,9EN8T)4:]*27/![TL1AYM2='%8:HHU
ML-7BN>C6A"I'6)R9!GV:<,YO@L[R;%3PF88"M&M1J1<N6:6E2A7@G%5L-B*;
ME1Q%"3Y*U&<X2T9_?QI.KZ5K^E:9KNA:GI^M:'K6GV6K:-K.DWMMJ6E:MI6I
M6T=YIVIZ9J-G)-:7^GW]I-#=65[:S2VUU;2QSP2/$ZL="OQ\_P""/_[3/_"S
M?@SJ/P*\4ZM]I\;_  5\K_A'/M]_YVHZW\*]5G?^R/(_M'7K_5]2_P"$#U=K
MCPM=_8=(TKPYX7\*WOPST2U\RYN7K]@Z_P E.-^%<;P3Q5G7#&.O*KE>,G2H
MUW'E6+P51*M@<9%;*.*PE2C6<4W[.4Y4V^:$DO\ 4/@[B;"<8<-91Q%@K*GF
M6%A4JT5+F>%Q<&Z6-PDGNY8;%0JTKM+GC&-1>[--E%%%?*GTH5\_?M9_\FK?
MM,?]F_?&7_U7/B2OH&OG[]K/_DU;]IC_ +-^^,O_ *KGQ)7M\-?\E'P__P!C
MO*O_ %/H'C\0_P#(@SS_ +$^9_\ J%7/X>****_V5/\ )<*_H$_X(5_\W2?]
MT1_]Z[7\_=?T"?\ !"O_ )ND_P"Z(_\ O7:_$_I%?\F;XQ_[M_\ ]:G(S]@\
M!/\ D[/"G_==_P#6:S@_H$HHHK_+L_T@"BBB@ HHHH **** "BBB@#_/WK[2
M_P""=O@G2OB!^VI^S]H6LW&H6UI8>,+KQM#)IDMM#<MJOPT\-ZY\1]"MY'NK
M2]B.GW>N>%=.M=6B6%+F?2IKV"SN["[D@OK?Y^^.'@G2OAI\:?B_\.-"N-0N
M]#^'_P 4?'_@G1KK5I;:?5;G2O"OBS5M"TZXU.>SM+"TFU":TL(9+V6UL;*V
MDN6D>"TMXBL*?6/_  2T_P"3[O@7_P!U._\ 5.?$*O\ 7?CC,?:^&G%^;8"I
M.G[3@;B#,<%5MRU(<^08O$X>IRN_+.-X2L[VDK.Y_EEP;@/9^(?"N68VG"?)
MQGD> Q=*_-3GRYYA</7IW5N:$K3C=6O%W1_8-1117^1!_J:%%%% !7/^+?"V
M@^.?"OB;P3XIL/[4\,>,?#^L^%O$>F?:KRR_M'0?$&G7.DZO8_;=.N+34+3[
M7I]W<6_VJQN[6\M_,\VUN(9T21>@HJZ56K1J4ZU&I.C6HSA5I5:4I4ZE*I3D
MIPJ4YQ:E"<))2A.+4HR2:::N14ITZU.I2JTX5:56$J=6E4BITZE.<7&=.I"2
M<9PG%N,HR3C*+:::9_G[T45^H?\ P2;^%/PW^,OQ^^)7@GXI^"O#_CGPQ=_L
M_>,7_LSQ!I\5W]AO+CQI\.-)_M?1+W":AX?\06NGZIJ%OIOB/0KO3M>TG[7-
M+IFHVD[>8/\ 8OBSB/#<(\.9MQ)C,/7Q6%R?"O%U\/AG36(JTHU(0E&C[64*
M;J)3O%3G",FK.4;W7^4'#&08CBG/\KX>PM>CAL3FN)6%HU\0INA3J2A.<75]
MG&=3DO"S<(RDKW496L_R\HKZA_:P_9/^)'[)'Q(E\$^-HO[5\/ZK]KO_ (?_
M ! L+.6VT'QSH-M+$DEQ;QO+<_V5X@TK[3:6_BGPM<7=S>:#>7-K+%=:KX?U
M7P]XAUSY>KT<IS;+<]RW!9QD^,H9AEF84(XC!XS#RYJ5:E*ZNKI2A.$E*G6H
MU(PK4*T)T:U.G5ISA'@S3*\PR7,,7E6:X2M@<QP-:5#%86O'EJ4JD;.SLW&<
M)Q<:E*K3E.E6I3A5I3G2G"<BOT"_8#_;:\5?LH_$C3]$U;5/M?P*\<^(-,@^
M(_A_46U*XL_#7VN6TTV?XF>'(=-LM4U"U\0>'M/2.;5[#3--N_\ A-M!TY/#
M][:-JEIX4UOPU^?M%<O$?#N4\5Y+C\@SS"0QF6YC0E1KTI)<\'O2Q&'FU)T<
M5AJBC6PU>*YZ-:$*D=8G3D&?9IPSF^"SO)L5/"9A@*T:U&I%RY9I:5*%>"<5
M6PV(IN5'$4)/DK49SA+1G]_&DZOI6OZ5IFNZ%J>GZUH>M:?9:MHVLZ3>VVI:
M5JVE:E;1WFG:GIFHV<DUI?Z??VDT-U97MK-+;75M+'/!(\3JQT*_EZ_X)=?M
MU_\ "D_%4?P-^,GC/^S_ ((^)_M/_"':EK<7GZ=\-O'FH:C;3)YVMS7T'_",
M?#_Q/Y^J-X@\ZUU#1M'\53Z;XED_X1C3-0\?>(+O^H6O\K_$WPXS;PTXCJY+
MCY2Q>!KQEB,GS:-"I2H9E@KI77,G"&,PSE"ECL-"I5^KU90:G.A6H5:O^E?A
MUQ_EGB'D%/-\%%8;&491P^;97*K"K6R_%\M[/E:G/"XCEE4P6(G"G[>FI)PA
M6I5J5,HHHK\Z/O0HHHH **** /Y^_P#@NI_S:W_W6[_WD5?S]U_3K_P6TTG2
MIOV;/AIKLVF:?+KFF_''2-)T[69+*V?5;#2M:\!?$"\UG3++46C-W:Z?JUWH
M&A76IV4$T=M?W.BZ3/=1RRZ;9M#_ #%5_IQ]&O&1Q/A%P_1C"47E^,SW!SDV
MFJDIYUCL>IQ2VBH8Z-.SUYH2>S1_G5](/"RP_BGGM:4U)8_"Y+BH))ITXPRC
M!X%PE?>3G@Y3NM.6<5NF?UC?\$@O O\ PB/[&FB>(/[4_M#_ (6C\0?'GCK[
M)]A^R?V'_9]]:_#/^RO/^V7/]I^=_P *Z_MO[=Y.G^7_ &Q_9OV-_P"S_M]]
M^H5?G[_P2T_Y,1^!?_=3O_5Q_$*OT"K^!/%/$UL5XE<?5:\_:3CQ?Q#AHRY8
MQM1P>:8K"8:%H1BG[/#T*5/F:YY\O/4E*<I2?]O^&N'I8;P]X(IT(<D)<*Y%
MB)+FE*];%Y;AL5B)WG*3_>5ZU2IRI\L>;EA&,%&*****^"/M@HHHH ^?OVL_
M^35OVF/^S?OC+_ZKGQ)7\/%?W#_M9_\ )JW[3'_9OWQE_P#5<^)*_AXK^\_H
MA_\ ).<8?]CO _\ J S^)_I3_P#(_P"%?^Q/C?\ U-045^T?_!*'X$_#?]HW
MX;_M??"[XHZ+_:OA_5?^%'W5E>VK16VO>%]>MHOC)'IGBGPMJ<D%S_97B#2O
MM,ZV]PT%S9WMG<W^BZU8ZKX?U75M)O\ \_?VL/V3_B1^R1\2)?!/C:+^U?#^
MJ_:[_P"'_P 0+"SEMM!\<Z#;2Q))<6\;RW/]E>(-*^TVEOXI\+7%W<WF@WES
M:RQ76J^']5\/>(=<_H#+?$3(<?QQQ#X?U*GU/B'(_J5;#T*\X\F<8+&91@,U
MG7P,K1O7P?UR=+%8-\U54:2QM*52B\1'"?AN8<!YW@N#<AXYIT_K>19S]<I5
MZU&$N;*<7A<UQN6PHXU7E:CB_JL:F&Q:Y:3K57A*BIU50>*^7J***^]/B3]0
M_P#@G'^WS_PRKKUW\-OB+!]K^!7CGQ -8U;4;#3_ +1KWP^\57=GIVD2>,K=
M+*!]0\0>'[K3]+TNS\4^'MMWJ-M9Z=:ZYX0B;5+34_#GC/\ JUTG5]*U_2M,
MUW0M3T_6M#UK3[+5M&UG2;VVU+2M6TK4K:.\T[4],U&SDFM+_3[^TFANK*]M
M9I;:ZMI8YX)'B=6/\ ]?N)_P39_X*3?\*_\ [ _9X_:'U_\ XM__ *-H_P ,
M_B9K%S_R3_[L%AX-\97\[?\ )/\ _5VWA[Q#<R?\6_\ W6E:K+_PK_[)=_#_
M /D3Z0W@G+/(5^.N$,!*IG5*+J\197AKN>:X>E3268X+#1@_:9E0A!?6J%.4
M98ZA'VE*G4QT)1QG]3^!'C!')YT."^*L:J>45)*GD.8XBRCEN(J5&_J&,Q#F
MN3+ZTY/ZM6J1DL'6E[.I4A@I1>$_I$HHHK^"C^V0HHHH **** "OYR_^"XW@
MG2K#Q_\  'XCPW&H-KGBKP?XU\$ZC:R2VQTJ'2OA_K6BZ[HUQ90+:)=QZA<W
M?Q+UV/4Y9[ZXMIK:TTE+6TLI8+R:_P#Z-*_G[_X+J?\ -K?_ '6[_P!Y%7[C
M]'&O6I>,/"U.G.4(8FEG]"O%;5:4>',VQ*IR_NJOAZ-72WO4X]+I_C?C_1I5
M?"GB6=2"E/#U<CK4)/>G5EG^68=SC_>=&O6I_P"&I(_G[K^P;_@EI_R8C\"_
M^ZG?^KC^(5?Q\U_8-_P2T_Y,1^!?_=3O_5Q_$*OZ=^EK_P FXR7_ ++;+?\
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M17^V!_C^%?L'_P $3_\ DZGQ_P#]F_>*O_5C?"FOQ\K]@_\ @B?_ ,G4^/\
M_LW[Q5_ZL;X4U^7>-?\ R:KCC_L25?\ T]1/TCP@_P"3F<&_]CBG_P"FJQ_4
M+1117^4!_IP%%%% !1110!_/W_P74_YM;_[K=_[R*OY^Z_H$_P""ZG_-K?\
MW6[_ -Y%7\_=?ZB?1U_Y,WP=_P!W!_ZU.>'^;_CW_P G9XK_ .Z%_P"LUDX4
M445^V'X^?Z!%%%%?XGG^P 4444 <_P"+?%.@^!O"OB;QMXIOO[+\,>#O#^L^
M*?$>I_9;R]_L[0?#^G7.K:O?_8M.M[O4+O[)I]I<7'V6QM+J\N/+\JUMYIW2
M-OX)]6U?5=?U74]=UW4]0UK7-:U"]U;6=9U:]N=2U75M5U*YDO-1U/4]1O))
MKN_U"_NYIKJ]O;J:6YNKF62>>1Y79C_0I_P6._:PL]/T&W_9*\(R^?J^O?\
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M"VACTSPQH_A[Q1X+T'3+JSO_ .E3X-_M ?!G]H+09O$?P<^(?A_QSI]IY?\
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M5A4IRD\+"MRPJ4YPG*T)0DFT_P"K6BBBO\@#_50**** "BBB@ HHHH ****
M"OP\_P""V/P8_MSX;_#'X[:3IOF:AX$\077@7Q=<:=X8^U7DOA7QC%]OT#5?
M$?BFV<3Z;X?\+>)]'DT72+'4X)M.EU[XFNME>:;J%ZUKKG[AU\O?MJ_#/_A;
M_P"RC\=_ L=IX@U'4+OX?ZMX@T#2O"UO]KU[6/%7@9H/'7A'1+"Q6PU.?4/[
M:\3^&])TJZTVRLVU'4;.[N+'3)K34+BVO(/T#PKXCGPIXA\)YTJOL:-+.,-A
M,=)V<?[-S*7]G9BY1DG&7)@\56J0O;EJPA.,H3C&<?AO$O((<3<"<3Y0Z?M:
MU7*L1B<%%74O[0R^/U_ *+BU*/-B\-2IRM?FISG"49PE*$OXF****_UP/\N
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MM7[!U^/G_!;#_DU;P!_V<#X5_P#5<_%:OU'P4_Y.KP/_ -CNE_Z9K'YOXO\
M_)L^,O\ L3U/_3M$_EZK^P;_ ():?\F(_ O_ +J=_P"KC^(5?Q\U_8-_P2T_
MY,1^!?\ W4[_ -7'\0J_KWZ6O_)N,E_[+;+?_5%Q(?RO]%[_ )+_ #?_ +(_
M,/\ U=</GZ!4445_GB?W@%%%% !1110 4444 %%%% !1110 5_#Q^UG_ ,G4
M_M,?]G _&7_U8WB2O[AZ_AX_:S_Y.I_:8_[.!^,O_JQO$E?U[]$/_DH^,/\
ML28'_P!3V?RO]*?_ )$'"O\ V.,;_P"H2/GZBBBO[S/XG/V#_P"")_\ R=3X
M_P#^S?O%7_JQOA37]0M?R]?\$3_^3J?'_P#V;]XJ_P#5C?"FOZA:_P UOI0?
M\G5Q?_8DR;_TS4/]"/HX_P#)L\+_ -CC-O\ T[3"BBBOYX/W@**** "BBB@
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MO^2CX?\ ^QWE7_J?0/'XA_Y$&>?]B?,__4*N?P\4445_LJ?Y+A7] G_!"O\
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M.I\?_P#9OWBK_P!6-\*:_'ROV#_X(G_\G4^/_P#LW[Q5_P"K&^%-?ZO^-?\
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M]\9?_5<^)*_AXK^\_HA_\DYQA_V.\#_Z@,_B?Z4__(_X5_[$^-_]34?T"?\
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MX(^V/G[]K/\ Y-6_:8_[-^^,O_JN?$E?P\5_</\ M9_\FK?M,?\ 9OWQE_\
M5<^)*_AXK^\_HA_\DYQA_P!CO _^H#/XG^E/_P C_A7_ +$^-_\ 4U'[!_\
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M0^-M*\/030W=AJ%A=PV]AX\M-.TT>&--U75_#^H:3<:=;>*K7PKX>_S]\??
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ML+'$>'-*M*<HO <1Y9BH))-5)3P^88%PE?9*&,E.ZUYH16S9^/E%%%?Z.G\
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M !+_ ,F5X@_[-=FO_K)US_,?A[_D[V1_]G(RS_UIZ!_8-1117^4!_IP%%%%
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M75O- [QM_7M^PS^W-X,_:_\ !CVMTFG^%?C3X5T^&7Q[X"BFD%M=VPDAM/\
MA-O!/VN::[O_  ??W<T$-W:33W>J^#-5N[?0M=N+VVO?#7B7Q5_GM](#P2_U
M1Q-3C#A/ S_U6Q<W+-,#0CST^'L95J)1G2@O?I91C)S2HJTJ6 Q-\-STJ%;
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M#=%%%?Z9G^=P5^XG_!#WQW_9_P 5/CE\,_[*\[_A+OA_X=\=?VW]N\O^S_\
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MV#K\?/\ @MA_R:MX _[.!\*_^JY^*U?">"G_ "=7@?\ ['=+_P!,UC[3Q?\
M^39\9?\ 8GJ?^G:)_+U7]@W_  2T_P"3$?@7_P!U._\ 5Q_$*OX^:_L&_P""
M6G_)B/P+_P"ZG?\ JX_B%7]>_2U_Y-QDO_9;9;_ZHN)#^5_HO?\ )?YO_P!D
M?F'_ *NN'S] J***_P \3^\ HHHH **** "BBB@ HHHH **** "OX>/VL_\
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MI--:WME=0RVUU;2R03QR1.RG[_PY\0\\\..(*.<Y36E+"U94J.<99-MX7-,
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MK5G"E2I0E4JU:DE"G3IPBY3J5)R:C"$(IRE*348Q3;:2/XF/VL_^3J?VF/\
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MP_-]7P.%P^#H<W+S>QPM&%"ES<D80YN2$;\D(1O\,8JR11117&=1\_?M9_\
M)JW[3'_9OWQE_P#5<^)*_AXK^X?]K/\ Y-6_:8_[-^^,O_JN?$E?P\5_>?T0
M_P#DG.,/^QW@?_4!G\3_ $I_^1_PK_V)\;_ZFH_8/_@B?_R=3X__ .S?O%7_
M *L;X4U_4+7\O7_!$_\ Y.I\?_\ 9OWBK_U8WPIK^H6OQ/Z4'_)U<7_V),F_
M],U#]@^CC_R;/"_]CC-O_3M,****_G@_> HHHH S]6TG2M?TK4]"UW3-/UK0
M]:T^]TG6=&U:RMM2TK5M*U*VDL]1TS4].O(YK2_T^_M)IK6]LKJ&6VNK:62"
M>.2)V4_R,_\ !0_]BK5?V5OBC>:[X0\/Z@G[/_CC4(W^'VLMJ-SKT?AW59=/
M6\U;X?Z_J-Q:PW=AJ%A=PZK=>$8]5FU*YUSP9!;3CQ#XAU_1?&3:7_7M7'_$
M#X?^#/BIX,\0_#WXA>'=/\5>#?%6GOIFNZ%J:2&VO+8R1SPR1S020W=AJ%A=
MPV^HZ3JVG7%IJNC:K:66K:3>V6I65K=0_JWA)XI9CX8<0?7H0JX[(\PC##9Y
ME,:LH^VH*<90QN$@YQH+,\%[_P!6G67)4I5,1A)3HQQ#KTOS/Q1\-L!XCY%]
M3G.G@LYP,IXC)LSE2C+V-9P:G@\5)0E6>7XOW5B(4GS4ZM.ABHPJRH>QJ_P3
MT5]8_MC_ +*?C/\ 9.^+NL>#]9TW4)/ >M:AK&I_"?Q?<3QZE;>*O!D5]BRC
MN]5MM-TFT/C#0+2ZTZP\;:2NFZ;)8:K+%J%G9/X:UKPWJNJ_)U?ZCY-G&79_
ME6 SK*<52QN79EAJ>*PF)HRC.$Z=1:QERMJ%6E-2I5Z4FIT:\*E&HHU(2BO\
MW,VRK'Y'F6-RC-,-5PF89?B)X;$X>K"4)0J0>DES)<U.I!QJT:J7)6HSIU:;
ME3G&3*^D?V4_VFO&?[)WQ=TWXI^#['3]:B?3[CPUXO\ #&IB.*V\5>#-2OM-
MO]5T2/5!;75WH&H&[TG3=2TG7;"*62PU73;)K^QUK0WU70-5^;J*TS3*\OSO
M+L;E&:X2ECLNS'#U<)C,)63=.O0K1<9P;BXSA+7FA4IRA5I34:E*<*D(R49;
MF6.R?'X/-,LQ-7!YA@,13Q.$Q5%I5*-:E)2A)*2E"2Z3IU(RIU(.5.I"=.4H
MO^Z?X$_';X;_ +1OPWT7XH_"[6O[5\/ZKNM;VRNEBMM>\+Z];102:GX6\4Z9
M'/<_V5X@TK[3 UQ;K/<V=[9W-AK6BWVJ^']5TG5K_P#-W_@MA_R:MX _[.!\
M*_\ JN?BM7X5_L<?M6>,_P!D[XNZ/XPT;4M0?P'K6H:/IGQ8\(6]O'J5MXJ\
M&17V;V2TTJYU+2;0^,- M+K4;_P3JS:EILEAJLLMA>7K^&M:\2:5JO[2?\%<
M/B!X,^*G[$GP?^(7P]\0Z?XJ\&^*OCCX2U/0M=TQY#;7EL?A[\6H)HY(9XX;
MNPU"PNX;C3M6TG4;>TU71M5M+W2=6LK+4K*ZM8?X8I^$>,\,/&_@.>%G7QW"
M^:Y\I91F%2$G4PTU1KSEE68U8TXT/KM&%Y49P<5C<-%XB%.G.&(H4/[-J>*6
M%\1O!SC6.)C1P?$F69(XYK@83BH8B#JT(QS/ 4Y3E6^IU9M1JPDI/!XB2H3J
M5(3H5JW\U5?V#?\ !+3_ ),1^!?_ '4[_P!7'\0J_CYK^P;_ ():?\F(_ O_
M +J=_P"KC^(5?JGTM?\ DW&2_P#9;9;_ .J+B0_-/HO?\E_F_P#V1^8?^KKA
M\_0*BBBO\\3^\ HHHH **** "BBB@ HHHH **** "OX>/VL_^3J?VF/^S@?C
M+_ZL;Q)7]P]?P\?M9_\ )U/[3'_9P/QE_P#5C>)*_KWZ(?\ R4?&'_8DP/\
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M%%<_XM\4Z#X&\*^)O&WBF^_LOPQX.\/ZSXI\1ZG]EO+W^SM!\/Z=<ZMJ]_\
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M445_ Y_;@4444 %%%% !1110!^)G_!;WP3I5_P#!;X-?$>:XU!=<\*_%&_\
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M-7Y_KF:1>!HRIV3]^C[>6(3?NI46Y72:?\_=?OI_P0Y^']M+JOQ^^*=]X=U
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M/V=?#9;CL11J<L9<E:CA:M2G/EG&4)<LXQ?+.,HNUI1:NC^'BOV#_P"")_\
MR=3X_P#^S?O%7_JQOA37X^5^P?\ P1/_ .3J?'__ &;]XJ_]6-\*:_U+\:_^
M35<<?]B2K_Z>HG^;/A!_R<S@W_L<4_\ TU6/ZA:***_R@/\ 3@**** "BBB@
M KQ[X[? GX;_ +1OPWUKX7?%'1?[5\/ZKMNK*]M6BMM>\+Z];13QZ9XI\+:G
M)!<_V5X@TK[3.MO<-!<V=[9W-_HNM6.J^']5U;2;_P!AHKJP..QF6XS"YAE^
M)KX+'8*O3Q.$Q>&J2I5\/B*,E.E6I5(-2A.$TI1DGHT<V,P>%S#"8C X[#4<
M7@\71J8?%87$4XU:%>A5BX5*56G-.,X3BVFFC^&C]HSX"^,_V;/B[XM^%'C2
MRU!)=%U"ZE\-:[>Z='IMMXV\&2WUW!X<\;:3#;W^K6@T_7[2U,LEI;:MJ4FA
MZK%J?AK5+A-<T75+6W\.K^V?]K#]D_X;_M;_  WE\$^-HO[*\0:5]KO_ (?_
M ! L+.*YU[P-KUS%$DEQ;QO+;?VKX?U7[-:6_BGPM<7=M9Z]9VUK+%=:5X@T
MKP]XAT/^,CX@?#_QG\*_&?B'X>_$+P[J'A7QEX5U!],UW0M32,7-G<B..>&2
M.:"2:TO]/O[2:WU'2=6TZXN]*UG2KNRU;2;V]TV]M;J;_3KP6\7<'XFY+.AB
MU#"<59/0H+.<$G&,,9"7[N.;Y?!<K>%KU(VQ-&,6\NQ-2%"HW2KX.MB?\Z/%
M[PMQ?AUF\:V%<\5PSFU:N\IQ;4I3PDX_O)97CI:I8FC3E?#UI22Q^'A.M32J
MT<71P_'T445^V'X^:$>KZK#I5[H4.IZA%H>I:AIFK:CHT=[<II5_JNBVVK6>
MC:G>Z<L@M+K4-)M-?UVUTR]GA>YL+;6M6@M9(HM2O%FSZ**E1C%R<8QBYRYI
MM12<Y*,8*4FM924(0A=W?+&,=HI*G*4E%2E)J"Y8)MM1BY2FXQ3^%<\I2LK+
MFE*6[;/[!O\ @EI_R8C\"_\ NIW_ *N/XA5^@5?G[_P2T_Y,1^!?_=3O_5Q_
M$*OT"K_(?Q+_ .3C\?\ _9;<5?\ J]QY_J=X>?\ ) <#_P#9'\,_^J7!!111
M7Q)]@%%%% 'S]^UG_P FK?M,?]F_?&7_ -5SXDK^'BO[A_VL_P#DU;]IC_LW
M[XR_^JY\25_#Q7]Y_1#_ .2<XP_['>!_]0&?Q/\ 2G_Y'_"O_8GQO_J:C^@3
M_@A7_P W2?\ =$?_ 'KM?T"5_,5_P1+U?58?VD_B7H4.IZA%H>I? [5]6U'1
MH[VY32K_ %71?'OP_L]&U.]TY9!:76H:3::_KMKIE[/"]S86VM:M!:R11:E>
M+-_3K7X)])3!RPWB[Q!6E.,EF&#R+&0BDTZ<89+@< X2OHY.>!G4NM.6<5NF
M?MWT?,7'$>%F148PE%X'%YUA9MM-5)3S?&8Y3C;9*&,C"SUYH2>S04445^#G
M[4%%%% !1110!\O?M8?LG_#?]K?X;R^"?&T7]E>(-*^UW_P_^(%A9Q7.O>!M
M>N8HDDN+>-Y;;^U?#^J_9K2W\4^%KB[MK/7K.VM98KK2O$&E>'O$.A_Q\_';
MX$_$C]G+XD:U\+OBCHO]E>(-*VW5E>VK2W.@^*-!N99X],\4^%M3D@MO[5\/
MZK]FG6WN&@MKRRO+:_T76K'2O$&E:MI-A_=/7P;^W-^PSX,_:_\ !B75J^G^
M%?C3X5T^:+P%X]EAD%M=VPDFN_\ A"?&WV2&:[O_  ??W<T\UI=PP7>J^#-5
MN[C7="M[VVO?$OAKQ5_1G@1XT5^ LQI\/<0XNK/@O,*LM90E7ED.-K27^VX=
M*7M(X"K-N698:G&K9MXS#4?K'MX8O\#\:O".CQM@*F>Y%A:<.+L#3CI&<:$<
M[PE*-OJ>(;CR2QU*"4<OQ%25.Z2PF(J^P]A/"_QTT5V'Q ^'_C/X5^,_$/P]
M^(7AW4/"OC+PKJ#Z9KNA:FD8N;.Y$<<\,D<T$DUI?Z??VDUOJ.DZMIUQ=Z5K
M.E7=EJVDWM[IM[:W4W'U_H_0KT,50HXG#5J6(PV(I4Z^'Q%"I"M0KT*T%4I5
MJ-6FY4ZM*K3E&=.I"4H3A)2BW%IG\ 5J-;#5JN'Q%*K0Q%"K4HUZ%:G.E6HU
MJ4G"K2JTIJ,Z=6G.,H5*<XJ4))QDDTT%:$FKZK-I5EH4VIZA+H>FZAJ>K:=H
MTE[<OI5AJNM6VDV>LZG9:<TAM+74-6M- T*UU.]@A2YO[;1=)@NI)8M-LUAS
MZ*MQC)Q<HQDX2YH-I-PDXR@Y1;^&3A.4;JSY92CM)IPI2BI*,I)37+-)M*45
M*,U&27Q+GC&5G=<T8RW285_</^R9_P FK?LS_P#9OWP:_P#5<^&Z_AXK^W?]
MCG5]*UK]D[]FR\T;4]/U:TA^!WPPTF:ZTR]MK^VBU70/!VD:%KNF23VLDL2:
MAHNN:;J.C:M9,PN=-U6PO=.O(X;NUGA3^1OI>1D^&N$9J,G".>XR,I6?+&4\
M W&+ELI24)N*;O)0DU?E=OZE^BQ**XAXI@Y+GEDV$E&-US.,<<E*2CNU%S@I
M-*R<HI_$K_2-%%%?P4?VR%?-W[5G[,O@S]K'X1:E\+/&%]J&BRQZA;^)?"'B
M?3#)+<^%?&>FV.I6&E:W)I9N;6TU_3Q::MJ6FZMH5_+%'?Z5J5ZNGWVBZXFE
M:_I7TC17?E>:9ADF8X+-\JQ57 YCEV)I8O!XNBTJE"O1DI0FE)2A..G+.G4C
M.E5IN5.K"=.<HOBS++<#G& QF5YGAJ>,R_'T*F&Q>&K)NG6HU8N,XMQ<9QEU
MA4IRC4IS4:E.<*D8R7\''Q6^&?BKX-?$CQI\+/&UI]D\3^!O$&H>']3V6^I6
M]G??9)3]BUO2/[6L-+U"Z\/^(-/>TUWPYJ5QI]I_:V@ZCIVIQ0K!=QY\^K^Q
M;]N;]AGP9^U_X,2ZM7T_PK\:?"NGS1> O'LL,@MKNV$DUW_PA/C;[)#-=W_@
M^_NYIYK2[A@N]5\&:K=W&NZ%;WMM>^)?#7BK^2KXF?"GXD?!KQ5=^"?BGX*\
M0>!O$]IY[_V9X@T^6T^W6=OJ-_I/]KZ)>X?3_$'A^ZU#2]0M]-\1Z%=ZCH.K
M?9)I=,U&[@7S#_J#X1^+F3>)>34TZE+!<3X&E3IYQD]2I!5)U%"SS'+T^5XC
M 8B493:A%U,%4;P^(7+]7Q&)_P XO%+PNS;P\S:I:G5QG#N,JU)Y5FL*<G"$
M'*ZP&/:YE0QU!2C!.<E3QE-*O0?-[>AA_/J]!^%/Q-\5?!KXD>"_BGX)N_LG
MB?P-X@T_Q!IF^?4K>SOOLDH^VZ)J_P#9-_I>H77A_P 0:>]WH7B/3;?4+3^U
MM!U'4=,EF6"[DSY]17ZSB<-0QF&Q&#Q5&&(PN*H5<-B:%6/-3K4*].5*M2J1
M>DH5*<I0G%Z.+:/R_#XBOA,10Q6&JSH8G#5J6(P]:FW&I1KT9QJ4JM.2UC.G
M4C&<6MI),_MG_9/_ &L/AO\ M;_#>+QMX)E_LKQ!I7V2Q^('P_O[N*YU[P-K
MUS%*\=O<2)%;?VKX?U7[-=W'A;Q3;VEM9Z]9VUU%+:Z5X@TKQ#X>T3ZAK^%C
MX$_';XD?LY?$C1?BC\+M:_LKQ!I6ZUO;*Z66YT'Q1H-S+!)J?A;Q3ID<]M_:
MOA_5?LT#7%NL]M>65Y;6&M:+?:5X@TK2=6L/ZYOV3_VVO@S^UMH,7_"&:I_8
MGQ'TWP_::WXV^%FKM.->\,>;>2Z9=S:=J$ME9:?XQ\/PZA'#L\0:!YOV2SUC
MPY_PE&F^%M:UNWT*/_-WQJ\#<P\/\96SSA^ABLQX,Q,W-5(QJ8C$</3G))83
M,II2D\$YR4,#F55VE>&$QDUB_8U<;_H%X0^,N!XXPE')L]KX; <78>"A[.4J
M="AGL(1;>*R^#<8K&*,7/&9?35XVEBL+!X7VM+!_8-%%%?SP?O 4444 %%%%
M 'X^?\%L/^35O '_ &<#X5_]5S\5J_EZK^E7_@M[XVTJP^"WP:^'$UOJ#:YX
MJ^*-_P"-M.NHXK8Z5#I7@#PGJ>A:S;WL[7:7<>H7-W\2]"DTR*"QN+::VM-6
M>ZN[*6"SAO\ ^:JO]+OHQT:M+PGRVI4IRA#$YMG5>A)K2K2CC989U(]XJOAZ
MU+_%3DC_ #S^D56I5?$[,(4YJ4\/EF44:\5O3JRPD<0H2_O.C7HU/\-2(444
M5_01^%G]P_[)G_)JW[,__9OWP:_]5SX;KZ!KY._83\;:5X__ &//V===T:WU
M"VM+#X7>'?!,T>IQ6T-RVJ_#2!OAQKMQ&EK=WL1T^[USPKJ-UI,K3)<SZ5-9
M3WEI87<D]C;_ %C7^-_%E&KAN*N)L-7IRI5\/Q!G-"M2DK2IU:68XFG4IR7\
MT)Q<7YH_UDX7K4L1PUP[B*$U4HU\CRFM1J1^&I2JX##SISCY2A)27DPHHHKY
M\]P***Y_Q;XIT'P-X5\3>-O%-]_9?ACP=X?UGQ3XCU/[+>7O]G:#X?TZYU;5
M[_[%IUO=ZA=_9-/M+BX^RV-I=7EQY?E6MO-.Z1M=*E5K5*=&C3G6K5IPI4J5
M*$JE2K4J24(4Z<(IRG.<FHPA%.4I-))MV(J5*=&G4JU9PI4J4)5*M6I)0ITZ
M<(N4ZE2<FHPA"*<I2DU&,4VVDC^!>BBBO]K3_((*_8/_ ((G_P#)U/C_ /[-
M^\5?^K&^%-?CY7ZY_P#!%S5]*TW]K'Q19ZCJ>GV%WK_P.\7:3H5K>WMM:W.M
M:K#XQ^'FNS:9I,$\B2ZEJ$6AZ+K.LR65FLURFE:3J>HM&+2PNIHOS#QIC*?A
M7QPHQE)K(J\FHIR:C"I2G.5E?W80C*4GM&,7)V2;/T?PBE&/B7P:Y244\ZH1
M3DTES3A4A"-W]J4Y1C%;RDU%7;2/ZE:***_R>/\ 3D**** "BBB@#^7K_@MA
M_P G4^ /^S?O"O\ ZL;XK5^/E?KG_P %H]7TK4OVL?"]GIVIZ??W>@? [PCI
M.NVME>VUU<Z+JLWC'XAZ[#IFK002/+INH2Z'K6C:S'97BPW+Z5JVF:BL9M+^
MUFE_(RO]8?!:,H>%? RG&46\BH22E%Q;C.I5G"5G9\LX2C.+VE&2DKIIG^8W
MB[*,O$OC)QDI)9U7BW%IKFA"G"<;K[49QE&2WC).+LTT%%%%?IY^<']]'A+Q
M3H/CGPKX9\;>%K[^U/#'C'P_HWBGPYJ?V6\LO[1T'Q!IUMJVD7_V+4;>TU"T
M^UZ?=V]Q]EOK2UO+?S/*NK>&='C7H*_.W_@F'^T%I7QP_9:\&Z$SZ?:^,O@I
MI^D_"GQ1HUHUM!(NE>'=,@L_ ?B.+3CK6K:J-/U_PG:V=K<:OJ,.E6VJ^,]"
M\;0:-IT&FZ7$J_HE7^-_%>0XGA?B7/.'L52JTJN4YEBL&HUG&52="G5D\+6<
MX1A"I'$89T<1"I"$(5(58U(QC&22_P!9.&<[H<2</9-GN&J4ZM+-,OPV+<J*
MDJ<:U2FOK-%1E*<H2H8A5:$Z<ISE3G3E"4I2BVRBBBOGSW HHK\;/^"F7_!0
M+2OA;X,N/@S\ OB-I\WQC\0ZA?:3XWUSPC<6VK7/PQ\,6$FJZ1X@TQ?$6GZD
M(O"OQ1O=<M$TBVLH[>_\0^%M*M]?U6XC\):]-X(UJX^JX,X.SKCK/\#P_DF'
ME4Q&+JQC6Q4J=:6$R[#:NKC<=5I4ZCHX:C!2;DUS5)\M&DIUJD(2^:XMXLRC
M@S(\9GN<5U"AA:<I4L/&=*.*Q^(T5+"8*G5G3]MB*LW%))VIPYJM1QI0G-?C
M9_P45^.UG\?_ -J[XA>)- UK^W?!'A'[#\-O =ZBZ#)9R:#X16:/5;S2-3\/
MSWEMKWA_7O&]YXN\4>'-<N=0OKR_T'7-.+-8VT=KI.G?#M%%?ZW</Y+@^&\C
MRC(,!&V#R?+L)EV';C&,ZD,)0A1]M54$HNO7E%UJ\[7J5JE2I)N4FW_ESGF<
M8OB#.<TSO'.^+S;'XK'UTI2E&$\36G5]C3<FVJ-&,E1H0O:G1A"$4HQ2170>
M$O"VO>.?%7AGP3X6L/[4\3^,?$&C>%O#FF?:K.R_M'7O$&HVVDZ18_;=1N+3
M3[3[7J%W;V_VJ_N[6SM_,\VZN(8$>1>?K^B3_@DA^Q-_8=GIO[6GQ-TOQ!IG
MB>Z_M*#X+>'[]?[+LXO"NM:#_9MY\3+B&"].H:E_PE.GZQK&A^%K#6;/3].B
MT%+KQ=;6GB"#Q)X/UO0_FO$CCW+?#KA7'\08Z4)XE0GALGP$G[V99M5IS>$P
MJ2E&2H*476QM6+YJ&#I5JD(SJ*G2J?0^'_!.8<>\2X'(\%&<,.YPQ&;8V*]W
M+\KIU(+%8EMQE%UG&2I82E)6K8NI1IR<*;G4A^VGP\\$Z5\-/ '@;X<:%<:A
M=Z'\/_!_AGP3HUUJTMM/JMSI7A71;+0M.N-3GL[2PM)M0FM+"&2]EM;&RMI+
MEI'@M+>(K"G8445_DC7KU<37K8FO.56OB*M2O6JRUE4JU9NI4J2?\TYR<GYL
M_P!1J-&EAZ-+#T(*G1H4Z=&C3C\-.E2BH4X1\HPBHKR1^%?_  7&\$ZK?^ /
M@#\1X;C3UT/PKXP\:^"=1M9);D:K-JOQ T71==T:XLH%M'M)-/MK3X::['J<
ML]];W,-S=Z2EK:7L4]Y-8?SEU_6M_P %<?!.E>*OV*_&.NZC<:A#=_#3QA\/
M_&VA1V4MM';7>JW_ (DMOAQ-;ZLD]I<2SZ>NA_$#6;J.*SFL+D:K;:9.UV]I
M#=6-[_)37^DGT7\T_M#PJPF$O?\ L/.\YRNW)R\OMJU/.K<U_P!Y_P C?FY]
M+<WL[?N[O_/OZ1V6_4?$S%8JUO[9R?*<ROS\W-[*E4RB_+_R[_Y%7+R:WM[3
M[=E_1)_P1Q_:PL]0T&X_9*\72^1J^@_\))XQ^%&IW%WH-G9ZAH-U>0:MXG\
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MG^6KWHX[+76A.I*C3E4I4XYCA$IU<NKRG#V=252A4G]5Q6*IU?SWQ*\/\O\
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M3F&88FA@L#@J%3$XO%XFI&CA\/0I1<ZE6M5FU"$(13<I2:1_+6#P>+S#%X?
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MO&W@R6^NX/#GC;28;>_U:T&GZ_:6IEDM+;5M2DT/58M3\-:I<)KFBZI:V_\
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MFL?V=_:FHHVH7=U(_P!Q?\%'/V^?^&JM>M/AM\.H/LGP*\#>(#K&DZC?Z?\
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M\N&?-4Y*4;U:E.$O9R;P[XZX@=/^R>%,[Q-*M;V>*G@:N$P$KSA#_D88U8?
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M2U75M5U*YDO-1U/4]1O))KN_U"_NYIKJ]O;J:6YNKF62>>1Y79CGU] _!/\
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MZM/+\-4H0J-MTE]8Q,H:0E*5N=_K'1117\U']"!1110 4444 %%%% '\]?\
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M (1_6_B#\4?[0^W?:_\ A!? =_I_]A_9/L?D?VK_ ,+,NOAUYW]I_:9OL/\
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M?A_I_P#8_P!N^R?\(+9W_P +O._M#['Y_P#:O_"L[_PC_;GE_88?L/\ ;?\
M:']F;[S^S?LG]H7_ -I^;?&W_!'7]CSQ5JMOJ.A1_%'X:6D.GQ64FA>"?&\%
M_I5W<QW-W.^K7$WQ'T+X@:XNH3Q7$-G+':ZS;:4+:PM&@TR&[>^NKTHK]I\,
M.-N,Y9_0R^7%O$\L!#!XV4,"\^S5X.$FU4<HX9XOV,9.I.<[J"?/*4OBDV_R
M+Q&X/X2CD=?'1X6X=6-GB\'&>,6298L5**_=J,L0L+[:2Y(QA9S:Y(QCLDCC
M_P#AR?\ LK_]#_\ M _^%5\.?_G4U^#?[9_P3\*_LZ_M*_$GX-^"=0\0:IX8
M\'?\(?\ V9?^*;K3KW7I_P#A(/ /A;Q3>_;[K2=*T/3Y?*U#7+N&U^SZ7:[+
M..WCE\Z=)+B4HK^S_##.,VS#/\91Q^:9CC:,<GQ%6-+%XW$XFG&I'&Y?!5(P
MK59Q4U&<XJ:7,HSDD[2:?\C>(V599@<DPM7!9;@,'5EFM"G*KA<'A\/4E3>$
MQTG3<Z5.$G!RA"3BWRN48MJ\5;]Y/^')_P"RO_T/_P"T#_X57PY_^=370>%O
M^"-'[(OA_7K#5]6U+XP^.=/M/M7VCPMXI\9Z'::#JGVBSN+6+[?<>"?!_@[Q
M/']BGFCU&U_LSQ'IV^\M+=+W[7I[7=A=%%?D'$/%7%%'(,\K4>),^HUJ.3YG
M5I5:6<9A3J4JE/!5YPJ4YPQ"E"<))2A.+4HR2:::3/U3(N&N'*V=Y-2J\/Y)
M5I5<UR^G5I5,JP$Z=2G/%T8SIU(2H.,X3BW&49)QE%M--,^D?!/_  3M_8K^
M'^JW&LZ%^S[X/O[NYT^73)(?&UUXD^)>E+;37-I=/);Z%\1]<\5:'::@);*%
M8M6M=.AU6"V>[LX+V.TO[Z"X^HO!/P\\ ?#32KC0OAQX&\'^ -#N]0EU:ZT;
MP3X9T7PKI5SJL]M:6<^IW&G:%96%I-J$UI86-K+>R0M<R6UE:0/(8K>%4**_
MC_-.)N(\\YO[:X@SO-^;DYO[4S7'YAS>S_A\WUNO5O[._N7^'[-C^J\MX>R#
M)K?V1D>3Y5R\_+_9N68+ V]I_$M]5H4K<]ESV^*WO7.PHHHKQ#V HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OG[XI_LI_LW_&K^W9OB9\%OA_XEU?Q+_9G]M^
M*_[ M=&\>7O]C?V>FF_\7!\/C2O&]M]FMM*L--_T3Q!!YVC0?V)/YND2S64A
M17=E^9YEE.)CC,JS#'99C(<O)BLOQ5?!8F'+4A5CRU\-4IU8\M6G3J1M)6J4
MX37O1BUQX[+\OS3#RPF9X'!YCA9WY\-CL+1Q>'ES0G2ES4<1"I3ES4ZE2F[Q
M=X3G!^[*2?Q]XZ_X)!?L:>+O[*_X1_1/B#\+O[/^W?:_^$%\>7^H?VY]K^Q^
M1_:O_"S+7XB^3_9GV:;[#_8G]C^9_:%Y_:7]H;+#[#\V_'#_ ()"_LV?#3X+
M?%_XCZ%XW^.-WKGP_P#A=X_\;:-:ZMXE\!3Z5<ZKX5\)ZMKNG6^IP6?PTL+N
M;3YKNPACO8K6^LKF2V:1(+NWE*S(45_87ACQ;Q5C\CX;JX[B7B#&U:^,JQKU
M<7G.8XFI6BLYQ-)1JSK8F<JD52C&FE-M*FE#X4D?RGXB<,<-8'.<_I8+AW(\
M)2HX6G*C3PN48##TZ4GE.'J.5.%+#PC3DZDG4;BDW-N7Q-L^#O\ @FW^Q/\
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M\-2I0:ASSY%:T>>?+;F=RBBBO,/0"BBB@ HHHH **** "BBB@ HHHH ****
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MY)/5)MI/4T****X#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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B5H1K<OM(T:E2C2J5*2DH3G2ISE%RA%KU&BBBOX@/[&/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 22, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 22,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gyre Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12770 High Bluff Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">567-7770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GYRE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20049643_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20049643_8k.htm">ef20049643_8k.htm</File>
    <File>gyre-20250522.xsd</File>
    <File>gyre-20250522_lab.xml</File>
    <File>gyre-20250522_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20049643_8k.htm": {
   "nsprefix": "gyre",
   "nsuri": "http://ir.catalystbiosciences.com/20250522",
   "dts": {
    "inline": {
     "local": [
      "ef20049643_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "gyre-20250522.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gyre-20250522_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gyre-20250522_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250522to20250522",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20049643_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250522to20250522",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20049643_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-25-020353-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-020353-xbrl.zip
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MT2H;H7V&\X;O5;0A>>.I,(W0#*.E3090:#)AH, 058!2L)3 DIM-2<X2Y4A
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M9?%WK^O&;(Y_Q]DDW/]_4$L#!!0    ( -&%MUJV[<DRS,\  "/Y!  4
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MR(*'1(T:K\CVGU9"00@V2UM,&26&@^N:$$;:';MO)A0+VXXX ;&"!7+P)I[
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M:9]SZ.GCP\.@E8UU/)AJFC&]V4I5J\U61 GW&ERD<CK5@>(($6]7/.JKQ^9
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MPEC8[C*=L MAT EL;Z>,K#",:'NBA*2&%647!U#PKO+3W6&9I(LDGTO]$]$
MD<;PRMF3@\66&HS.JJX?#C7/^>JB4B,3)!/T2C#"K7G%'D[,OKEZLZB[I'_V
M]\C4A2C$:$2NT\^EMOU,K4F)+68O5]I&#WC*FEA-</).LP*%7:Y/.,6-U*6
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MM[W' H4+JM,J:T:)A'LV6A+RABU MIHJ[KQ6.T)H35&$I4H"6*#.JCJ"RHV
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MH/JH,\NN9OK::J9]G]XQ-6P;9N*AZ6Y"53JG[#>6S*'1C"$+\L\P1\0M@90
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MD,-RV65/-7JZ CY,)_VP"N0'%6,X:6?8F7*?B-B(.B0QK!B&XS'-D9@0YKE
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MO#*WX5=[18Q0ES#4K%+Q<MV:AR+S&VX4,Q+1^$'1E(RWS9MLR3W'+WE_/#2
M>&0$7Z*HUXZB/OD21?TC15%7UZFVN2T.=$Z6O1>XUZ !L7-*744*]F.GU'4
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M/WSZL@X[)'A+W*6^4]QER:WYVF,IS::7BY^]?W<6$.WKDZFIEVGV%YP? J@
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MUR*/@JB3YGUWQ@R[KBS_OQT/Z"R7/UFHYZ"\K2+.HEI\_-;%Y%R.!B=+8E]
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MD\+?RX&1,<-IP16C%NIJE_./W:?"AW654SN*<>>I:^,R=6JG#+YY%P/:IP4
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M8>2**N'^*C3RK Q2N[ORC"P/73@$5(%SY7LS*E(<%V42Y0PP% +6*,C%V5X
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MEE<@=I\%WVX4=YNPRTKBDXD8336'\:([!L="AAN1'4(..6E? 9$[C,J@R%N
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M0(4#BX:(+CC";G5$0NK9!4%U*ZJ:>_!@GJD^I#6A,IF 4,!I4V0/?$I!%59
M6STAQ>9 (QC%A4/5H8Y 63>3P=LO<W#FB2%A,F>21!!F+IG'R^^'=73/"H"!
M!S5,$N4R+$LZN!1#,;NX'"M^VR[)DGPF6I%H[L&#&L8BD?:DPE?G7:5ZA89J
MO9N#<_:)O[6U;DJJMYS._@=02P,$%     @ T86W6MJ+BAKI!0  #3\  !4
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MH[MAO-(7<I]KPK"PI7@/IWB#0KR[P^X6B\I]<CU0+I0+"$_WQF75Z._*HWP
MN<^E\;_)L@UFC=U@A9L]88"#=T9=B:?YPY!-N>2YO;0KO[*$8[Y!O)*^CX@_
MXA7N#_\#4$L! A0#%     @ T86W6D4:35RZ%@  CY@  !$
M ( !     &5F,C P-#DV-#-?.&LN:'1M4$L! A0#%     @ T86W6K;MR3+,
MSP  (_D$ !0              ( !Z18  &5F,C P-#DV-#-?97@Q+3$N:'1M
M4$L! A0#%     @ T86W6MFZ<I:8!P  +!T  !0              ( !Y^8
M &5F,C P-#DV-#-?97@U+3$N:'1M4$L! A0#%     @ T86W6N9+,IY: P
MV0\  !$              ( !L>X  &=Y<F4M,C R-3 U,C(N>'-D4$L! A0#
M%     @ T86W6GURQ[!["   ,%8  !4              ( !.O(  &=Y<F4M
M,C R-3 U,C)?;&%B+GAM;%!+ 0(4 Q0    ( -&%MUK:BXH:Z04   T_   5
M              "  >CZ  !G>7)E+3(P,C4P-3(R7W!R92YX;6Q02P4&
/  8 !@"( 0  ! $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ef20049643_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gyre-20250522.xsd" xlink:type="simple"/>
    <context id="c20250522to20250522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2025-05-22</startDate>
            <endDate>2025-05-22</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20250522to20250522"
      id="Fact_359ed5aa6f874131abcc4d1c735cfe4f">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20250522to20250522"
      id="Fact_8d102cfac2804bb1af8424746fbd3d3f">0001124105</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20250522to20250522"
      id="Fact_803372887618415e9ccf7b8533d26b1b">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20250522to20250522"
      id="Fact_dd6d5cf9e32642a38dbf8c16e598d8bc">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20250522to20250522"
      id="Fact_91d6e86721774baab49dc237ba25a245">2025-05-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20250522to20250522"
      id="Fact_7d8d572fcadb403f829276e949e4b529">Gyre Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250522to20250522"
      id="Fact_bb33256183f446c882f5d1684a551878">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20250522to20250522"
      id="Fact_8d92bb4352284594bf8f114142f7cd82">000-51173</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250522to20250522"
      id="Fact_604b812ba52e4d6aa852e41a4047d38c">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250522to20250522"
      id="Fact_96c889a6cedd469aa0e4388bfc85c6b3">12770 High Bluff Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20250522to20250522"
      id="Fact_38cfc3bdc0f746a683101739e3306dd5">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20250522to20250522"
      id="Fact_723f14caecbb499fae776ec99a9fde6a">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20250522to20250522"
      id="Fact_ee3abc12dea04833ad6016a8592ed7e5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250522to20250522"
      id="Fact_f8a4873ff60d4696a05c54271ecc9758">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250522to20250522"
      id="Fact_4705e864a627483e937b0a093d7f02a6">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250522to20250522"
      id="Fact_1decce6865864e78941566c22eb0a586">567-7770</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20250522to20250522"
      id="Fact_d707c5485fd54de3b817a493b39c119b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20250522to20250522"
      id="Fact_33cabbdd46b242f3b0eae829fb1afa0a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20250522to20250522"
      id="Fact_1f84ec9409714b849ecd5b6a2426f3e5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20250522to20250522"
      id="Fact_b8c6869e52b740718b2129a6a90155a0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20250522to20250522"
      id="Fact_f63e077c2a484cdfb63d6ed4219b486f">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250522to20250522"
      id="Fact_3a2598ab4fe7485585be5ae98a5fbc34">GYRE</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250522to20250522"
      id="Fact_fd1d647883b84fb896f40088c7b767e6">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
